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“La mente è come un paracadute: 
 Funziona solo se si apre” 
Albert Einstein 
 
 
 
 
 
 
 
 
 
 
 
 Alla mia famiglia: 
 Insieme di mattoni di unione, pazienza ed amore  
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RIASSUNTO 
 
Il mio lavoro di dottorato è stato incentrato sulla progettazione e sintesi di 
peptidi e peptidomimetici coinvolti nella terapia antiretrovirale ed antitumorale. 
La prima parte del mio lavoro, della durata di due anni e mezzo, è stata svolta 
presso il Dipartimento di Farmacia dell’Università Federico II di Napoli, presso il 
gruppo di ricerca guidato dal Prof. Vincenzo Santagada ed è stata focalizzata alla 
ricerca di nuovi potenti inibitori in vitro della proteina NC del virus dell’HIV-1. 
La necessità di disporre di nuovi farmaci anti-HIV costituisce sicuramente 
un’esigenza di interesse globale. Gli effetti collaterali e lo sviluppo di fenomeni di 
resistenza hanno limitato molto l’impiego terapeutico delle classi di medicinali 
attualmente disponibili, per cui l’attenzione del mondo della ricerca è da tempo 
rivolta verso  nuovi target  per lo sviluppo di nuovi farmaci antiretrovirali. 
La nostra attenzione si è rivolta, pertanto, ad un innovativo eccellente target 
molecolare, la proteina chaperonica nucleocapsidica (NC), costituita da 55 
aminoacidi basici, caratterizzata dalla presenza di due domini “zinc-fingers” 
altamente conservati, che gioca un importante ruolo in diversi steps della replicazione 
del virus dell’HIV, tra cui il processo di trascrizione.  
La proteina NC svolge un ruolo di mediatore nella reazione di annealing 
dell’acido nucleico TAR RNA con la sua copia di DNA cTAR attraverso la fusione 
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delle loro strutture secondarie, per la formazione di un ibrido più stabile di 
RNA/DNA.  
 La protein Tat  (elemento transattivatore nel processo di trascrizione) aumenta 
la frequenza della trascrizione a seguito del legame alla regione TAR all’ estremità 5’  
del trascritto nascente. In assenza di Tat, il processo di trascrizione inizia 
normalmente ma si riduce l’ efficienza del processo, infatti la polimerasi non 
trascrive più di 100 nucleotidi. 
Al fine di individuare nuovi potenti inibitori della proteina NC, durante il mio 
periodo di dottorato mi sono occupata della sintesi di tre nuove serie di molecole. In 
particolare, basandoci su precisi requisiti strutturali, consistenti nella presenza di 
sostituenti amminoacidici carichi positivamente nelle posizioni 2,6 dell’anello 
antrachinonico, mi sono occupata della sintesi in soluzione di tre nuove serie di 
composti denominate 2,6-AQ-Gly-X (composti 4a-4l ),2,6-AQ-L-Ala-X (composti 
5a-5l) e 2,6-AQ-D-Ala-X (6a-6l) caratterizzate dalla presenza di linker differenti tra 
lo scaffold antrachinonico e le catene laterali aminoacidiche. 
 Le nuove serie di composti sono state saggiate,  al fine di verificare la loro 
capacità di inibire la formazione del complesso Tat-TAR e l’attività chaperonica della 
proteina NC, da parte del  gruppo di ricerca della Prof.ssa Barbara Gatto presso il 
Dipartimento di Scienze Farmaceutiche dell’Università degli Studi di Padova, 
mediante studi di: High Throughput Screening (HTS), Fluorescence Quenching 
Assay (FQA); Saggio NAME (Nucleocapsid Annealing-Mediated Electrophoreis). 
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Inoltre, al fine di ampliare lo spettro di informazioni relative all’interazione tra i 
composti sintetizzati e gli acidi nucleici di interesse, sono stati eseguiti studi di ESI-
MS presso l’RNA Institute – University of New York sotto la supervisione del Prof. 
Dan Fabris. 
I composti sono stati ottenuti seguendo un’eccellente strategia sintetica che ha 
condotto ad alte rese e purezza elevata. 
Confrontando le strutture chimiche delle due serie di derivati dei quali ad oggi si 
sono resi disponibili i risultati dell’attività biologica (serie 2,6-AQ-Gly-X, composti 
da 4a a 4i e serie 2,6-AQ-L-Ala-X, composti da 5a a 5i), caratterizzate dalla presenza 
di linker diversi, possiamo concludere che la presenza di un residuo di ornitina in 
catena laterale, conferisce caratteristiche favorevoli per potenziare l’attività inibitoria 
di entrambe le serie di composti antrachinonici testati.  
Questo assunto è confermato dal fatto che i composti 4g e 5g presentano 
un’elevata attività sia nel saggio NAME che in quello di HTS. Dai risultati emerge 
altresì che il derivato 4h, caratterizzato da una lisina come residuo amminoacidico 
terminale, rappresenti il composto più promettente della serie con la glicina come 
spacer. 
La considerazione che la catena della lisina, più lunga di un unità metilenica 
rispetto a quella dell’ornitina, conferisca migliori proprietà di inibizione della 
proteina NC, suggerisce che la lunghezza della catena gioca sicuramente  un ruolo 
fondamentale sull’attività di tali composti.  
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In conclusione, abbiamo dimostrato che questi nuovi derivati interagiscono 
preferenzialmente con le strutture non-canoniche di TAR e cTAR, stabilizzano le loro 
strutture dinamiche e interferiscono con l’attività della proteina NC. Il lead 
compound è rappresentato dal composto 4h, che agisce come legante nei confronti sia 
di TAR che di cTAR,  così come potente inibitore della proteina NC (IC50= 2.12 μM).  
La seconda parte del mio lavoro di dottorato è stata svolta presso il Dipartimento 
di Chimica Biologica dell’Università di Vienna, presso il gruppo di ricerca del Prof. 
Christian Becker, avendo come tutor la Dottoressa Claudia Bello ed è stata incentrata 
su nuove strategie sintetiche per la glicosilazione  di un frammento della proteina 
IGFBP6.  
In passato sono stati sviluppati molti metodi per ottenere in vitro peptidi e 
proteine selettivamente glicosilati con saccaridi complessi, basati su strategie di 
sintesi chimica o usando altri approcci basati sull´utilizzo di enzimi. Gli approcci 
enzimatici, tuttavia, hanno come svantaggio il fatto di sviluppare reazioni di 
glicosilazione non quantitative a causa del limitato accesso degli enzimi ai substrati, 
soprattutto quando la glicosilazione è condotta in fase solida, cioè con il substrato 
ancora legato alla resina. Tale limitazione conduce all´ottenimento di rese basse dei 
prodotti di glicosilazione.  
Per superare tale problemi in un primo approccio è stato proposto di modificare i 
peptidi inserendo il PEG alla loro estremitá N-terminale. Il peptide glicosilato poteva 
essere recuperato dopo rimozione proteolitica del PEG alla fine della glicosilazione. 
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Successivamente, tale nuova strategia basata sull’utilizzo del PEG, è stata 
associata all’introduzione di un ausiliario rimuovibile mediante radiazioni UV, che 
facesse da tramite per la glicosilazione e ligazione di diversi peptidi.  
A tal fine mi sono occupata di sintetizzare tale ausiliario, utilizzato 
precedentemente dal gruppo di ricerca per la glicosilazione di analoghi della mucina, 
in rese più elevate al fine di poter applicare tale strategia ad un nuovo target, la 
proteina IGFBP6. 
L´insulin growth factor (IGF), é un elemento fondamentale per la crescita 
fisiologica ed é anche implicato in numerose patologie incluso il cancro; se ne 
classificano due distinti sottoptipi denominati 1 e 2. 
La sua attività è modulata da una famiglia di proteine dotate di elevata affinità 
per l´IGF-1 e IGF-2: in particolare IGFBP6, target di nostro interesse, si distingue per 
la propria marcata affinità di legame per l’IGF-2 rispetto all’IGF-1.  
Il principale ruolo della proteina IGFBP6 consiste nell’inibizione delle azioni 
dell’IGF-2, ma studi recenti hanno anche indicato come presenti anche delle attività 
indipendenti rispetto a tale target, che includono l’inibizione del processo di 
angiogenesi e l’induzione alla migrazione delle cellule tumorali. IGFBP6 possiede 
caratteristiche chimiche peculiari: è composto da tre domini strutturali ed inoltre sia 
l´estremità N-terminale che quella C-terminale si presentano ricche in cisteine. 
L’estremità C-terminale possiede azioni e funzioni indipendenti dall’IGF. Tutte 
le IGFBP sono soggette ad un gran numero di modifiche post-traslazionali che 
influenzano le loro azioni mediate da un gran numero di proteasi. 
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Le IGFBP3 e IGFBP4 vengono N-glicosilate,  mentre IGFBP 5 e 6 vengono O-
glicosilate. Il processo di glicosilazione non agisce direttamente influenzando le 
azioni di tali proteine, ma diminuisce la loro percentuale di legame nei confronti dei 
glicosamminoglicani, inibendo il loro processo proteolitico.  
IGFBP6 è coinvolta nella patogenesi di fenomeni tumorali: cancro al seno, alla 
prostata, al colon, al collo e alla testa del pancreas, alle ovaie e nel neuroblastoma 
rappresentano infatti le patologie nelle quali il ruolo di tale proteina è stato elucidato 
chiaramente. 
Pertanto, la sua inibizione può rivelarsi un interessante target per la terapia del 
cancro, soprattutto per quanto riguarda bambini o giovani pazienti adolescenti, dove 
una specifica inibizione del recettore IGF-2 risulta essere vantaggiosa per bloccare gli 
alti livelli di IGF-2 autocrino, senza andare a perturbare la crescita fisiologica 
mediata dalla presenza di IGF-1. 
Mi sono quindi occupata della sintesi, mediante strategia sintetica in fase solida 
via Fmoc, di un frammento peptidico di 27 amminoacidi,  parte della sequenza dell’ 
insulin-like growth factor-binding protein6(IGFBP6): 
127-ARPQDVNRRDQQRNPGTSTTPSQPNSA-153 
 A tale peptide è stato aggiunto in seguito un amminoacido modificato la 
Fmoc-Thr(GalNAc-Ac3)-OH, al cui coupling è seguita una reazione di 
iodoacetilazione. L’ultima fase del progetto ha previsto l’esecuzione di tests 
preliminari per legare il peptide all’ausiliario. Attualmente il progetto viene 
continuato dal gruppo del Prof. Christian Becker e dalla Dottoressa Claudia Bello. 
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This PhD thesis is divided into two parts, the first part carried out at the 
Department of Pharmacy at the University Federico II of Naples, the second one at 
the Department of Biological Chemistry at the University of Vienna. Both of them 
are focused on design and synthesis of peptides and peptidomimetics involved in 
pharmacological therapies. 
 
Abstract Unit 1 
The development of new anti-HIV-1 drugs is a global need,  due to the 
resistance and the side effects arising from the therapies currently in use, for this 
reason we focused on an innovative target, the nucleocapsidic chaperonic 
protein(NC) of HIV-1 virus, which is involved in many steps of the virus replication, 
expecially the trascription. Moreover it plays a role of mediator in the annealing 
reaction of TAR with cTAR. 
2,6-Dipeptidyl-anthraquinones are a promising class of nucleic acid-binding 
compounds that act as NC inhibitors in vitro. We designed, synthesized and tested 
new series of 2,6-disubstituted-anthraquinones, which are able to bind viral nucleic 
acid substrates of NC. We demonstrated that these novel derivatives interact 
preferentially with non-canonical structures of TAR and cTAR, stabilize their 
dynamics structures, such as bulge and loop, and interfere with NC chaperone 
activity.  
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1.1 Acquired immune deficiency syndrome (AIDS):  human immunodeficiency 
virus type (HIV-1) 
 
Acquired immunodeficiency syndrome (AIDS) of humans is caused by two 
Lentiviruses, human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2) [1]. 
Both HIVs are the result of multiple cross-species transmissions of simian 
immunodeficiency viruses (SIVs) naturally infecting African primates. Most of these 
transfers resulted in viruses that spread in humans to only a limited extent. However, 
one transmission event, involving SIV from chimpanzees in southeastern Cameroon, 
gave rise to HIV-1 group M, the principal cause of the AIDS pandemic. 
Acquired Immune Deficiency Syndrome (AIDS) was first recognized as a new 
disease in 1981 when increasing numbers of young homosexual men succumbed to 
unusual opportunistic infections and rare malignancies. A retrovirus, now termed 
human immunodeficiency virus type 1 (HIV-1), was subsequently identified as the 
causative agent of what has since become one of the most devastating infectious 
diseases to have emerged in recent history.  
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Figure 1: HIV prevalence in individuals aged 15-49 years. 
HIV-1 spreads by sexual, percutaneous and perinatal routes, however, 80% of 
adults acquire HIV-1 following exposure at mucosal surfaces, and AIDS is thus 
primarily a sexually transmitted disease.  
Since its first identification almost three decades ago, the pandemic form of 
HIV-1, also called the main (M) group, has infected at least 60 million people and 
caused more than 25 million deaths (Figure 1) [2]. 
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Developing countries have experienced the greatest HIV/AIDS morbidity and 
mortality, with the highest prevalence rates recorded in young adults in sub-Saharan 
Africa. Although antiretroviral treatment has reduced the toll of AIDS- related deaths, 
access to therapy is not universal, and the prospects of curative treatments and an 
effective vaccine are uncertain. Thus, AIDS will continue to pose a significant public 
health threat for decades to come.  
Ever since HIV-1 was first discovered, the reasons for its sudden emergence, 
epidemic spread and unique pathogenicity have been a subject of intense study. A 
first clue came in 1986 when a morphologically similar, but antigenically distinct, 
virus was found to cause AIDS in patients in western Africa [3]. 
1.2 The origin of the virus  
HIV-1 has long been suspected to be of chimpanzee origin [4] however, until 
recently, the perceived lack of a chimpanzee reservoir left the source of HIV-1 open 
to question. These uncertainties have since been resolved by non-invasive testing of 
wild-living ape populations.  
It is now well established that all naturally occurring SIVcpz (SIV chimpanzees) 
strains fall into two subspecies-specific lineages, termed SIVcpzPtt and SIVcpzPts, 
respectively, that are restricted to the home ranges of their respective hosts. Viruses 
from these two lineages are quite divergent, differing at about 30%-50% of sites in 
their Gag, Pol, and Env protein sequences [5]. 
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Interestingly, population genetic studies have shown that central and eastern 
chimpanzees are barely differentiated, calling into question their status as separate 
subspecie.  However, the fact that they harbor distinct SIVcpz lineages suggests that 
central and eastern chimpanzees have been effectively isolated for some time.  
In addition, molecular epidemiological studies in southern Cameroon have 
shown that SIVcpzPtt strains show phylogeographic clustering, with viruses from 
particular areas forming monophyletic lineages, and the discovery of SIVgor (SIV 
gorillas) has identified a second ape species as a potential reservoir for human 
infection [6].  
Collectively, these findings have allowed the origins of HIV-1 to be unraveled 
[7]. 
HIV-1 is not just one virus, but comprises four distinct lineages, termed groups 
M, N, O, and P, each of which resulted from an independent cross-species 
transmission event. Group M was the first to be discovered and represents the 
pandemic form of HIV-1[8]; it has infected millions of people worldwide and has 
been found in virtually every country on the globe.  
Group O was discovered in 1990 and is much less prevalent than group M. It 
represents less than 1% of global HIV-1 infections, and is largely restricted to 
Cameroon, Gabon, and neighboring countries.  
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Group N was identified in 1998,  and is even less prevalent than group O; so far, 
only 13 cases of group N infection have been documented, all in individuals from 
Cameroon.  
Finally, group P was discovered in 2009 in a Cameroonian woman living in 
France [9]. Despite extensive screening, group P has thus far only been identified in 
one other person, also from Cameroon [10]. Although members of all of these groups 
are capable of causing CD4
+
 T-cell depletion and AIDS.  
How humans acquired the precursors of HIV-1 groups M, N, O, and P is not 
known; however, based on the biology of these viruses, transmission must have 
occurred through cutaneous or mucous membrane exposure to infected ape blood 
and/or body fluids. Such exposures occur most commonly in the context of  bushmeat 
hunting. Whatever the circumstances, it seems clear that human–ape encounters in 
west central Africa have resulted in four independent cross-species transmission 
events. Molecular clock analyses have dated the onset of the group M and O 
epidemics to the beginning of the twentieth century [10].  
 In contrast, groups N and P appear to have emerged more recently, although the 
sequence data for these rare groups are still too limited to draw definitive 
conclusions. Obviously they differ vastly in distribution within the human population. 
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1.3 HIV Replication  
HIV can only replicate inside human cells and begins its cycle by entries those 
cell that present CD4 receptors on their surface. This receptor is usually found on 
immune cells such as T-cells on macrophages. The gp120 surface protein interacts 
with the CD4 marker resulting in attachment of the virus to the host cell. However, 
for entry, the virus also needs a co-receptor in addition to the CD4 receptor i.e. 
CCR5(R5) on macrophages and CXCR4(X4) on T cells [11]. 
The interaction between the CD4-gp 120 complex and co-receptor is required 
for changes in the cell membrane to facilitate viral entry. 
The HIV-1 genome encodes nine open reading frames. Three of these encode 
the Gag, Pol, and Env polyproteins, which are subsequently proteolyzed into 
individual proteins common to all retroviruses. The four Gag proteins, MA (matrix), 
CA (capsid), NC (nucleocapsid), and p6, and the two Env proteins, SU (surface or 
gp120) and TM (transmembrane or gp41), are structural components that make up the 
core of the virion and outer membrane envelope. The three Pol proteins, PR 
(protease), RT (reverse transcriptase), and IN (integrase), provide essential enzymatic 
functions and are also encapsulated within the particle. 
HIV-1 encodes six additional proteins, often called accessory proteins, three of 
which (Vif, Vpr and Nef) are found in the viral particle. Two other accessory 
proteins, Tat and Rev, provide essential gene regulatory functions, and the last 
protein, Vpu, indirectly assists in assembly of the virion [11].   
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The retroviral genome is encoded by an ∼9-kb RNA, and two genomic-length 
RNA molecules are also packaged in the particle. Thus, in simplistic terms, HIV-1 
may be considered as a molecular entity consisting of 15 proteins and one RNA. 
The HIV-1 promoter is located in the 5′ LTR and contains a number of 
regulatory elements important for RNA polymerase II transcription. Sites for several 
cellular transcription factors are located upstream of the start site, including sites for 
NF-κB, Sp1, and TBP. These cellular factors help control the rate of transcription 
initiation from the integrated provirus  and their abundance in different cell types or 
at different times likely determines whether a provirus is quiescent or actively 
replicating.  
Despite the importance of these factors, transcription complexes initiated at the 
HIV-1 promoter are rather inefficient at elongation and require the viral protein Tat to 
enhance the processivity of transcribing polymerases. Under some conditions, Tat 
may also enhance the rate of transcription initiation.  
Tat increases production of viral mRNAs ∼100-fold and consequently is 
essential for viral replication. It is not yet clear which features of the HIV-1 promoter 
cause initiating transcription complexes to be poorly processive, but experiments in 
which the TATA box and downstream sequences have been interchanged with 
different promoters suggest an important role for these regions[12]. 
In the absence of Tat, polymerases generally do not transcribe beyond a few 
hundred nucleotides, though they do not appear to terminate at specific sites. It is not 
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yet clear how Tat causes transcribing polymerases to become sufficiently processive 
to completely transcribe the ∼9-kb viral genome, but recent experiments suggest that 
Tat may assemble into transcription complexes and recruit or activate factors that 
phosphorylate the RNA polymerase II C-terminal domain (CTD), including the 
general transcription factor TFIIH and other novel kinases.  
These findings support a model in which Tat enhances phosphorylation of the 
CTD, a process known to occur as RNA polymerase II converts from an initiating to 
an elongating enzyme. 
Unlike typical transcriptional activators, Tat binds not to a DNA site but rather 
to an RNA hairpin known as TAR (trans-activating response element), located at the 
5′ end of the nascent viral transcripts. An arginine-rich domain of Tat helps mediate 
binding to a three-nucleotide bulge region of TAR, with one arginine residue being 
primarily responsible for recognition. NMR studies of TAR complexed to arginine 
show a base-specific contact between the arginine side chain and a guanine in the 
RNA major groove. The complex is stabilized by additional contacts to the phosphate 
backbone and by formation of a U-A: U base triple between a bulge nucleotide and a 
base pair above the bulge (Figure 2)[12]. 
NMR studies of the full-length 86–amino acid Tat protein have suggested that a 
hydrophobic core region of about 10 amino acids adopts a defined structure but that 
the rest of the molecule, including the arginine-rich RNA-binding domain, is 
22 
 
relatively disordered. It seems likely that Tat requires interactions with cellular 
proteins in addition to TAR to adopt a stable structure.  
Aside from proteins of the transcription apparatus, another protein is needed to 
bind to the loop of the TAR hairpin, apparently helping to stabilize the Tat-TAR 
interaction.  
 
Figure 2: HIV replication cycle. 
Reverse transcription is a critical step for retroviral replication. Reverse 
transcription is catalyzed by Reverse Transcriptase(RT) and consists of a complex 
series of events that culminate in the synthesis of a linear double-stranded DNA copy 
of the viral RNA genome. The conversion of a single-stranded RNA genome to a 
double-stranded DNA is achieved by employing two obligatory strand transfer steps, 
minus-strand transfer and plus-strand transfer. During the assembly of virus, both 
host tRNA and viral RNA are selectively packaged into the virions (Figure 3) [13]. 
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                                          Figure 3: Mechanism of reverse transcription.  
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1.4  AIDS and HIV-1 Antiretroviral Drug Therapy  
HIV infection is characterized by a gradual decrease in T cell levels (in 
particular T cells carrying the CD4 marker on their surface which include T helper 
cells) through three main mechanisms: direct viral killing of infected cells; increased 
rates of apoptosis in infected cells and killing of infected CD4+T cells by CD8 
cytotoxic lymphocytes that recognize infected cells [14]. 
When CD4
+
T cell number decline below a critical level, cell  mediated 
immunity is lost. AIDS is the final stage of HIV infection and is used to describe a 
highly decimated CD4
+
T cell count and the appearance of various opportunistic 
infections as a result of the progressive failure of the immune system. 
Any secondary condition, symptom, or other disorders caused by an AIDS 
weakened immune system is a complication of AIDS.  The opportunistic infections 
associated with AIDS are not restricted to the immune system. Some of the more 
common are caused by: Pneumocystis pneumonia, Cytomegalovirus, Candidiasis, 
Mycobacterium tuberculosis and Herpes simplex. AIDS causes also common 
diseases affecting the gastrointestinal tract, neurological and psychiatric effects, 
increasing incidence of tumors and cancers (Kaposi’s sarcoma, Burkitt’s lymphoma, 
and cervical cancer in HIV infected women due to the human papillomavirus) [15]. 
Currently there are different classes of anti-HIV drugs that however have several 
limitations especially the resistance of the virus. 
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HIV-1 reverse transcriptase (RT) contributes to the development of resistance to 
all anti-AIDS drugs by introducing mutations into the viral genome. Until today, the 
most significant advance in the medical management of HIV-1 infection has been the 
treatment of patients with antiviral drugs, which can suppress HIV-1 replication to 
undetectable levels.  
The discovery of HIV-1 as the causative agent of AIDS together with an ever-
increasing understanding of the virus replication cycle have been instrumental in this 
effort by providing researchers with the knowledge and tools required to prosecute 
drug discovery efforts focused on targeted inhibition with specific pharmacological 
agents [15]. To date, an arsenal of 24 Food and Drug Administration (FDA)-
approved drugs are available for treatment of HIV-1 infections. These drugs are 
distributed into six distinct classes based on their molecular mechanism and 
resistance profiles: (1) nucleoside-analog reverse transcriptase inhibitors (NNRTIs), 
(2) non–nucleoside reverse transcriptase inhibitors (NNRTIs), (3) integrase 
inhibitors, (4) protease inhibitors (PIs), (5) fusion inhibitors, and (6) coreceptor 
antagonists [16]. 
HIV-1 entry exploits several host proteins for a set of intricate events leading to 
membrane fusion and virus core release into the cytoplasm.  
The treatment of HIV-1 infection was revolutionized in the mid-1990s by the 
development of inhibitors of the reverse transcriptase and protease [17] two of three 
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essential enzymes of HIV-1, and the introduction of drug regimens that combined 
these agents to enhance the overall efficacy and durability of therapy. 
Since the first HIV-1 specific antiviral drugs were given as monotherapy in the 
early 1990s, the standard of HIV-1 care evolved to include the administration of a 
cocktail or combination of antiretroviral agents (ARVs). The advent of combination 
therapy, also known as HAART, for the treatment of HIV-1 infection was seminal in 
reducing the morbidity and mortality associated with HIV-1 infection and AIDS [18]. 
Combined antiretroviral therapy dramatically suppresses viral replication and 
reduces the plasma HIV-1 viral load (vLoad) to below the limits of detection of the 
most sensitive clinical assays (<50 RNA copies/mL) resulting in a significant 
reconstitution of the immune system [19] as measured by an increase in circulating 
CD4
+
 T-lymphocytes. Importantly, combination therapy using three antiretroviral 
agents directed against at least two distinct molecular targets is the underlying basis 
for forestalling the evolution drug resistance [20]. 
1) NRTIs (Nucleoside/Nucleotide reverse transcriptase inhibitors). 
NRTIs were the first class of drugs to be approved by the FDA. NRTIs are 
administered as prodrugs, which require host cell entry and phosphorylation by 
cellular kinases before enacting an antiviral effect. Lack of a 3′-hydroxyl group at the 
sugar (2′-deoxyribosyl) moiety of the NRTIs prevents the formation of a 3′-5′-
phosphodiester bond between the NRTIs and incoming 5′-nucleoside triphosphates, 
resulting in termination of the growing viral DNA chain. Chain termination can occur 
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during RNA-dependent DNA or DNA-dependent DNA syntheses, inhibiting 
production of either the (−) or (+) strands of the HIV-1 proviral DNA. 
Currently, there are eight FDA-approved NRTIs: abacavir (ABC), didanosine 
(ddI), emtricitabine (FTC), lamivudine (3TC), stavudine (d4T), zalcitabine (ddC), 
zidovudine (AZT) and tenofovir disopropyl fumarate (TDF) (Figure 4) [21]. 
 
Figure 4: Nucleos(t)ide reverse transcriptase inhibitors and X-ray crystal structure of HIV-1 RT in complex 
with DNA primer/template chain terminated with ddAMP and with an incoming dTTP. 
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Resistance to NRTIs is mediated by two mechanisms:  
1. ATP-dependent pyrophosphorolysis, which is the removal of NRTIs from 
the 3′ end of the nascent chain, and reversal of chain termination;  
2. increased discrimination between the native deoxyribonucleotide substrate 
and the inhibitor. 
 
2)Non-Nucleoside Reverse Transcriptase Inhibitors  
NNRTIs inhibit HIV-1 RT by binding and inducing the formation of a 
hydrophobic pocket proximal to, but not overlapping, the active site.  
The binding of NNRTIs changes the spatial conformation of the substrate-
binding site and reduces polymerase activity. The NNRTI-binding pocket only exists 
in the presence of NNRTIs and consists of hydrophobic residues (Y181, Y188, F227, 
W229, and Y232), and hydrophilic residues such as K101, K103, S105, D192, and 
E224 of the p66 subunit and E138 of the p51 subunit.  
Unlike NRTIs, these non/uncompetitive inhibitors do not inhibit the RT of other 
Lentiviruses such as HIV-2 and Simian Immunodeficiency Virus (SIV).  
Currently, there are four approved NNRTIs: etravirine, delavirdine, efavirenz, 
and nevirapine, and several in development, including rilpivirine in Phase III (Figure 
5) [22]. 
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Figure 5: Non–nucleoside RT inhibitors and the X-ray crystal structure of HIV-1 
RT complexed with etravirine. 
NNRTI resistance generally results from amino acid substitutions such as L100, 
K101, K103, E138, V179, Y181, and Y188 in the NNRTI-binding pocket of RT. 
3) Integrase Inhibitors (INIs or InSTIs) 
Integrase was the most recent HIV-1 enzyme to be successfully targeted for drug 
development . Raltegravir (RAL, MK-0518) was FDA approved in 2007, and other 
integrase inhibitors, including Elvitegravir (EVG, GS-9137) are progressing through 
clinical development [23].  
Integrase catalyzes 3′ end processing and viral DNA and strand transfer. All 
integrase inhibitors in development target the strand transfer reaction and are thus 
referred to as either INIs or more specifically, integrase strand transfer inhibitors 
(InSTIs).  
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The selective effect on strand transfer is a result of a now well-defined 
mechanism of action in which the inhibitor binds only to the specific complex 
between integrase and the viral DNA and  interacts with the two essential magnesium 
metal ion cofactors in the integrase active site and also the DNA.  
Therefore, all InSTIs are comprised of two essential components: a metal-
binding pharmacophore, which sequesters the active site magnesiums, and a 
hydrophobic group, which interacts with the viral DNA as well as the enzyme in the 
complex.  
InSTIs are therefore the only class that interacts with two essential elements of 
the virus, the integrase enzyme as well as the viral DNA, which is the substrate for 
integration. 
The recent co-crystallization of the foamy virus integrase DNA complex or 
intasome with both RAL and EVG corroborates the biochemical mechanism and 
provides a structural basis for understanding the unique breadth of antiviral activity 
that has been observed for InSTIs across all HIV-1 subtypes as well as other 
retroviruses, such as HIV-2 and XMRV (Figure 6) [24].  
In the cocrystal structure, the general architecture and aminoacids within the 
active site of the foamy virus intasome are highly conserved with other retroviral 
integrases, as are the immediate surrounding interactions with InSTIs. The common 
mechanism of action and conserved binding mode for InSTIs also has important 
implications for understanding resistance to the class. 
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Figure 6: Integrase strand transfer inhibitors and the crystal structure of prototype human foamy 
virus integrase (as a model of HIV-1 IN) complexed to dsDNA and Raltegravir.  
           
             4) Protease Inhibitors (PI) 
The HIV-1 protease is the enzyme responsible for the cleavage of the viral gag 
and gag-pol polyprotein precursors during virion maturation.  
Ten PIs are currently approved (Figure 7) [25]: amprenavir (APV), atazanavir 
(ATZ), darunavir (TMC114), fosamprenavir, indinavir (IDV), lopinavir (LPV), 
nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and tipranavir.  
Because of its vital role in the life cycle of HIV-1 and relatively small size (11 
kDa), it was initially expected that resistance to protease inhibitors would be rare.  
32 
 
However, the protease gene has great plasticity, with polymorphisms observed 
in 49 of the 99 codons, and more than 20 substitutions known to be associated with 
resistance. The emergence of protease inhibitor resistance likely requires the stepwise 
accumulation of primary and compensatory mutations  and each PI usually selects for 
certain signature primary mutations and a characteristic pattern of compensatory 
mutations [25]. 
Unlike NNRTIs, primary drug-resistant substitutions are rarely observed in the 
viral populations in protease inhibitor-naive individuals. 
 
Figure 7: Protease inhibitors and the crystal structure of HIV-1 protease complexed with atazanavir. 
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5) Fusion Inhibitors 
The crystal structure of the gp41 ectodomain and of the ectodomain partnered 
with an inhibitory peptide (C34) revealed that the fusion-active conformation of gp41 
was a six-helix bundle in which three N helices form an interior, trimeric coiled coil 
onto which three antiparallel C helices pack.  
Peptide fusion inhibitors were designed based on the discovery that two 
homologous domains in the viral gp41 protein must interact with each other to 
promote fusion, and that mimicry of one of these domains by a heterologous protein 
can bind and disrupt the intramolecular interactions of the virus protein.  
Alpha-helical peptides homologous to the leucine zipper domain of gp41 had 
significant antiviral activity against HIV-1, and this activity depended on their 
ordered solution structure. Rational design of helical inhibitors ultimately produced a 
molecule (T-20, enfuvirtide) with potent antiviral activity in vivo (Figure 8) [26]. 
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 Figure 8: Fusion inhibitors - mechanism of action. Enfuvirtide binds to the transmembrane domain and 
prevents fusion to the host cell and viral entry.  
 
Resistance to early alpha-helical inhibitors was shown to be mediated by 
mutations in the amino-terminal region of gp41, which provide further evidence for 
binding of these peptides to the virus.  
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6) Small-Molecule CCR5 Antagonists 
Small-molecule CCR5 antagonists bind to hydrophobic pockets within the 
transmembrane helices of CCR5. This site does not overlap the binding sites of either 
CCR5 agonists or HIV-1 envelope. Instead, drug binding induces and stabilizes a 
receptor conformation that is not recognized by either. Thus, these molecules are 
considered allosteric inhibitors. Ideally, a small-molecule inhibitor of CCR5 would 
block binding by HIV-1 envelope, but continue to bind native chemokines and allow 
signal transduction [27]. 
Most small-molecule inhibitors, however, are pure antagonists of the receptor. 
Oral administration of small-molecule antagonists has been shown to inhibit 
viral replication in macaque models and to prevent vaginal transmission. Thus far, 
three antagonists (VCV, MVC, and Aplaviroc) have been shown to inhibit virus 
replication in humans [28]. 
The compound MVC was approved for therapeutic use by the FDA in 2007. 
Small-molecule CCR5 inhibitors have been used to select for drug resistance in 
peripheral blood mononuclear cell cultures (PBMC), which express CCR5 and 
CXCR4, as well as a variety of other chemokine receptors that could potentially 
substitute for HIV-1 coreceptors.  
 
 
36 
 
1.5  New target for inhibitors of HIV-1 replication: NC (Nucleocapsid Protein) 
Despite the success of protease and reverse transcriptase inhibitors, and due to 
the toxicity of the anti-HIV drugs and their adverse reactions  (responsible for failures 
of many treatments),  new drugs to suppress HIV-1 replication are still needed [29]. 
Several other early events in the viral life cycle (stages before the viral genome 
is inserted into host cell DNA) are susceptible to drugs, including virus attachment to 
target cells, membrane fusion and post-entry events such as integration, accessory-
gene function and assembly of viral particles. 
New molecular targets that can be exploited for the development of new classes 
of HIV drugs are hence actively sought. Moreover regarding HIV-1, viral proteins 
involved in the regulation of numerous viruses recognize nucleic acids.  
One of these unexplored targets can be precisely represented by the HIV-1 
nucleocapsid  NCp(NC), which is required at several steps of HIV replication: during 
retro-transcription it favors the strand transfer steps through its chaperone activities, 
allowing the helix destabilization and the annealing of viral nucleic acids. 
In the absence of NC, the synthesis of DNA catalyzed by Reverse Transcriptase 
(RT) is in fact incomplete and the enzyme stops at stable structured sites in the 
template strand [30].  
  The sequence TAR( Transactivation Responsive Element) is a stable bulge–
loop RNA in the R region of the HIV genome required for efficient viral 
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transcription. TAR RNA binds HIV-1 Tat (transactivator of transcription), and TAR–
Tat complex inhibition has been thoroughly explored. 
Interestingly, TAR is not only necessary for Tat-mediated functions, but it also 
plays a critical role in the minus strand transfer during reverse transcription: the TAR 
RNA located at the 50-end of the viral genome must be paired with its 
complementary DNA sequence, cTAR,  synthesized by RT in the minus-strong-stop 
DNA. The annealing of TAR/cTAR, not favored due to the very stable secondary 
structures of TAR and cTAR, is catalysed by NC: melting of secondary structures of 
viral RNA and DNA makes them available for re-pairing in alternative combinations 
during the strand transfer to form more stable annealed hybrids (Figure 9) [31]. 
 
Figure 9: Representation of the major groove of free TAR (on the left) and of the Tat-bound TAR 
(on the right). A22 and A27 are represented in red; U23 in green and G26 in yellow . 
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So the HIV-1 nucleocapsid protein (NC) represents a key protein: structurally  is 
a small  55-amino acids basic protein with two CysCysHisCys zinc-binding domains, 
that strongly bind Zn
2+
 and specifically recognizes the Ψ-site of the viral RNA.  
It plays a number of crucial roles in the viral lifecycle, including reverse 
transcription and RNA encapsidation.  
NC destabilizes nucleic acid structures and promotes the formation of annealed 
substrates for HIV-1 reverse transcription elongation.  Short helical nucleic acid 
segments bordered by bulges and loops, such as the Trans-Activation Response 
element (TAR) of HIV-1 and its complementary sequence (cTAR), are nucleation 
elements for helix destabilization by NC and also preferred recognition sites for 
threading intercalators.  
Its activity is mainly related to its 11amminoacids located in the N-terminus 
domain, instead destabilizing power is due to its zinc fingers domain (Figure 10) [32]. 
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Figure 10: Three-dimensional NMR structure of a NC/RNA hairpin complex. 
 The N-terminal 12 residues of NC (shown in red in the Figure 9) bind to the 
major groove to the RNA stem (shown in gray) through the electrostatic interactions. 
The function of NC relies on two interactions, electrostatic and π- π stacking 
interactions, with nucleic acids, NC protein appears to have two distinct domains 
implied in binding with nucleic acids.  
The N-terminal basic helix of NC interacts nonspecifically with the major 
groove of the RNA stem by electrostatic interactions [33] and is responsible for the 
aggregation of NC/nucleic acid complexes. 
The zinc finger domain interacts with specific base sequences in particular with 
preference for TG or UG rich regions [34]. The binding of zinc fingers to nucleic 
acids is responsible for destabilizing their secondary structure.  
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NMR further showed that phenylalanine in the first zinc finger (ZF1) and 
tryptophan in the second zinc finger (ZF2) engaged in aromatic π- π stacking 
interaction with the G residues in the single-stranded GGAG tetraloop as shown in 
Figure 9.  
NC was observed to have highly specific interactions with bases in the nucleic 
acids loop since binds specifically to exposed (unpaired) nucleobases of RNA or 
DNA. 
NC is crucial for many processes of viral life cycle in which interactions 
between nucleic acids and NC are the key. For example, NC is involved in the 
recognition and packaging for RNA genomes, in virus assembly, in selectively 
packaging tRNA primer and in many annealing steps during the reverse transcription 
[35]. 
As a nucleic acid chaperone protein, NC catalyzes nucleic acids  conformational 
rearrangement that leads to the most thermodinamically stable structure. The 
chaperone activity of NC is believed to be derived from two main consequences of 
the nucleic-acid/NC interactions in this system.  
Fist, NC lowers the energy cost of bringing two complementary strands of 
nucleic acids together by screening the negative charges of two oligonucleotides and 
perhaps through the binding of the N-terminal basic helix to the double-stranded stem 
of the hairpins.  
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The NC chaperone activity allows the protein to be a cofactor of RT and 
promote several annealing reactions during the HIV-1 reverse transcription process: 
NC makes it possible for RT to copy the stem-loop sequences in RNA and DNA 
templates by melting the structured sequences. 
In additions, NC has been shown to facilitate the annealing of cellular tRNA 
onto the PBS of the viral RNA, the annealing of complementary PBS sequences in 
plus-strand transfer and the annealing of the transactivation response (TAR) region of 
the viral RNA to the complementary sequences (cTar) during minus-strand transfer 
[35]. 
NC inhibition represents therefore a new molecular approach in antiretroviral 
therapy: drugs targeting NC are currently not available, although different and 
unrelated classes of molecules such as peptidomimetics [36], RNA aptamers [37], 
zinc ejector agents [38], nucleomimetics and nucleic acid [39] binding drugs have 
been proposed.  
Regard peptidomimetics: an alternative strategy to inhibit NC functions is to 
design peptides that can directly compete with NC for the binding to its RNA and 
DNA substrates i.e. cyclic peptides mimicking the spatial orientation of Phe16 and 
Trp37 residues in the hydrophobic plateau and containing two basic residues to 
mimic Arg26 and Arg32.  
Anyway, the activity of the leading compound was not so satisfactory. Attempts 
are actually performed to better mimic the NC hydrophobic plateau, in order to 
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increase the activity of these peptidomimetics i.e. with small peptides able to 
specifically recognize NC targets that are composed of a cluster of Trp residues 
surrounded by basic residues.  
These peptides were able to compete with NC target sequences binding mainly 
through stacking interactions between the Trp residues and the oligonucleotide bases 
and to stabilize the cTAR secondary structure inhibiting the NC-directed melting of 
the cTAR sequence. 
The second class is represented by RNA aptamers which were selected using the 
SELEX method, obtaining aptamers of about 40 nucleotides in length [37]. Their 
secondary structures correspond to stem-loops in which the stems are rich in GC base 
pairs and the loops contain G and U residues.  
 Zinc ejector agents are oxidizing agents that are able to attack the sulfhydryl 
group of the Cys residue and eject the zinc, rendering the zinc fingers and by 
extension, the whole protein, inactive. Many classes of Zinc ejector agents and zinc 
ligands have been identified: NOBA (3-nitrosobenzamide), DIBA (disulfide 
benzamide).However, these compounds elicit serious side effects since they target 
cellular proteins binding zinc and this impairs their use in therapy [38]. 
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Non zinc ejecting NC binders were also identified and these represent  antagonists of 
the strong binding of  NC to oligonucleotides. Many of them contain a xanthenyl ring 
structure while other had a related fluorescein or gallein-like structure (containing a 
xanthene ring substituted by two hydroxyls in positions 4’ and 5’, lead compound 
tetrachlorogallein). Hydroxyls groups likely play a critical role since they were found 
to be critical for binding to NC and are the only feature that the compounds share. 
Probably hydroxyl groups bind to the amide nitrogen of Gly35 with additional 
contacts at the carbonyl oxygen of Gly40 and Lys33 of NC and it is thought that 
these compounds might interfere with NC’s ability to stack its aromatic residues with 
the bases of its nucleic acids target. Compounds able to inhibit NC activity by 
binding do not show any structure-activity correlation [40]. 
The last class is represented by intercalators:  actinomycin D (widely used anti-
cancer drug that inhibits the DNA-dependent DNA/RNA synthesis through DNA 
intercalation and binding to the minor groove) was the most active, but the main 
problem is that it interacts with a large range of nucleic acids, giving a poor 
specificity. As a consequence, a clinical use of such a molecule will likely generate 
critical side effects and the emergence of resistant strains[41]. 
Is now clear that the nucleocapsid protein of HIV-1 (NC) , is critical for proper 
viral packaging and replication, owing to its highly conserved nature, for these 
reasons it represents an ideal drug target [42]. 
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As described above, NC mediates the annealing of TAR with cTAR by melting 
their secondary structures and making extensive complementary sequences available 
to anneal into a more stable RNA/DNA hybrid , as represented in Figure 11.  
 
 
 
Figure 11: Sequence and secondary structure of constructs replicating TAR RNA and cTAR 
DNA, which were employed in the assays, performed for our compounds. Heat 
refolding or NC-mediated annealing can lead to the formation of the Hybrid 
TAR/cTAR. 
 
Based on this and analogous functions in the viral lifecycle, it has become 
more clear that NC could represent an excellent molecular target for antiretroviral 
therapy, pursued by different approaches in recent years [42]. 
As starting point for the present PhD project, we decided to explore more in 
details the possibility of design and synthesize novel anthraquinonic derivatives able 
to bind the TAR RNA. 
 In particular the research group to which I belong has recently published that 
threading intercalators characterized by a polyaromatic nucleus di-substituted at 
opposite positions with charged amino acid side chains are preferential binders of 
dynamic RNA regions like the bulge and loop structure of TAR [43].  
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Similarly, molecules comprising an aromatic nucleus conjugated through a 
linker with cationic chains (“tripartite motif”) were demonstrated to be able to inhibit 
TAR recognition by the Tat protein. This is particularly interesting given the parallels 
between Tat and NC as RNA chaperones and TAR binders by NC. 
For this reason, searching for new NC inhibitors, the research group above 
mentioned identified a class of compounds consisting of intercalating anthraquinones 
that are known for their nucleic acid-binding properties. They demonstrated that 
these threading intercalators were able to inhibit NC in vitro by stabilizing dynamic 
nucleic acid structures and counteracting NC-induced destabilization. In particular, 
they shown that 2,6-derivatives bearing a -Ala linker followed by different charged 
amino acids were able to bind preferentially to typical NC substrates, which resulted 
in their stabilization [44].  
With the aim of exploring the Structure-Activity-Relationship (SAR) of these 
putative NC inhibitors, we have synthesized novel series of 2,6-dipeptidyl 
anthraquinones, which display different linkers between the anthraquinonic scaffold 
and the cationic side chains. 
 Named 2,6-AQ-Gly-X, 2,6-AQ-L-Ala-X, and 2,6-AQ-D-Ala-X, these three 
new series comprise respectively the compounds 4a-4l,   5a-5l and 6a-6l that are 
shown in Figure 12. 
 
 
47 
 
 
Figure 12: New series of compounds,  named 2,6-AQ-Gly-X, 2,6-AQ-L-Ala-X and 2,6-AQ-D-Ala-X,  
respectively 4a-4l, 5a-5l and 6a-6l. 
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3.1 Synthesis of 2,6-disubstituted-anthraquinone derivatives 
Compounds 4a-4l,  5a-5l and 6a-6l  were obtained by standard solution 
synthesis according to the procedure reported previously for 2,6-disubstituted 
anthraquinones [43], which was appropriately modified to obtain the synthetic 
strategy summarized in Scheme 1.  
 
Scheme 1. General synthetic pathway for the preparation of the anthraquinone derivatives included in the 
study. Reagents and conditions: (i) Pyridine, DMF; (ii) 33% Diethylamine, THF; (iii) TFA/H2O; (iv) HBTU, 
DMAP, DMF; (v) 33% Diethylamine, THF; (vi) TFA/H2O. 
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The general strategy is based on the condensation of 2,6-diaminoanthraquinone 
nucleus 1 with (9H-fluoren-9-yl)methyl-2-chloro-2-oxoethylcarbamate (Fmoc-Gly-
Cl) 2a,  with (9H-fluoren-9-yl)methyl-1-chloro-1-oxopropan-2-yl carbamate (Fmoc-
L-Ala-Cl) 2b or with 2c [(9H-fluoren-9-yl)metil-1-chloro-1-oxopropan-2-yl 
carbamate (Fmoc-D-Ala-Cl)] in presence of pyridine in DMF, stirring at room 
temperature for two hours.  
Reaction mixture was dried and then treated with 33% diethylamine in THF in 
order to remove Fmoc- protecting group and successively reacted with trifluoroacetic 
acid in H2O (9:1; v/v) giving intermediates 3a, 3b and 3c, respectively.  
Intermediates 3a, 3b and 3c were successively coupled with the selected 
protected amino acid in presence of HBTU and DMAP in DMF. Fmoc- and Boc- 
protecting groups were removed with 33% diethylamine in THF and trifluoroacetic 
acid in H2O (9:1; v/v), respectively, giving the desired compounds 4a-4l, 5a-5l and 
6a-6l.  
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3.2 Synthesis of intermediates 2a, 2b and 2c 
Fmoc-Gly-Cl (2a), Fmoc-L-Ala-Cl (2b) and Fmoc-D-Ala-Cl (2c) were prepared 
stirring at reflux for 30 minutes the corresponding commercially available Fmoc-
amino acids treated with an excess of thionyl chloride in anhydrous CH2Cl2 (Scheme 
2). 
 
                         
 Scheme 2:  Preparation of Fmoc-Gly-Cl (2a), Fmoc-L-Ala-Cl (2b) and Fmoc-D- Ala-Cl (2c). 
 
Final compounds were purified by preparative RP-HPLC and were fully 
characterized by mass spectrometry, 
1
H-NMR and 
13
C-NMR. NMR and MS data for 
all final compounds were consistent with proposed structures. 
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Chapter 4 
Experimental Section 
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4.1 Materials and Methods.  
Protected α-amino acids were purchased from Bachem (Bubendorf, Switzerland) 
and Merck-Novabiochem (Darmstadt, Germany). The following protecting groups 
were employed for the selected amino acids: Fmoc for α-aminogroups and for the 
side-chains of 4-(amino)-piperidine-4-carboxylic acid, piperidine-4-carboxylic acid, 
and 4-(aminomethyl)-cyclohexanecarboxylic acid; Boc for the side chains of Lys, 
Orn, diaminobutyric, diaminopropionic, and 4-amino-phenylalanine residues.  
Coupling and cleavage reagents, as well as solvents and other chemicals, were 
purchased from Sigma–Aldrich.  
RP-HPLC preparative purification was routinely performed on a Shimadzu 
prominence LC-20 AP system equipped with a multiwavelength prominence SPD-
20A UV-VIS detector. The stationary phase consisted of a Supelco Ascentis® C18 
column (10 µm, 25cm x 21.2 mm). The mobile phase consisted of solvent A: 100% 
acetonitrile in 0.1% TFA, and solvent B: 100% H2O in 0.1% TFA. The operational 
conditions involved a linear gradient of 5-70% acetonitrile with 0.1% TFA, which 
developed in 30 minutes at a flow rate of 30 mL/min. Product purity was assessed by 
analytical RP-HPLC that used a Macherey-Nagel Nucleosil 100-5 C18 column (5 
μm, 4 x 125 mm). The column was connected to a Rheodyne model 7725 injector, a 
Shimadzu-10 ADsp HPLC system, a Shimadzu SPD-20 A/SPD-20 AV UV-VIS 
detector set to 254 nm.  
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The analytical determinations employed solvent A: 100% acetonitrile in 0.1% 
TFA, and B: 100% H2O in 0.1% TFA. The operational conditions involved a linear 
gradient of 5-70% acetonitrile with 0.1% TFA, which developed in 30 minutes at a 
flow rate of 1 mL/min. Purity of all final compounds was ≥95%.  
Mass spectrometric analyses of the final products were performed on API 2000 
Applied Biosystem triple-quadrupole mass spectrometer.  
NMR spectra were recorded on a Varian Mercury Plus 400 instrument. 
Chemical shifts are given as δ and are referred to Me4Si as internal standard. The 
following abbreviations are used to describe peak patterns, when appropriate: s 
(singlet), bs (broad singlet), d (doublet), dd (double doublet), t (triplet), m (multiplet).  
All oligonucleotides were synthesized by Metabion International AG 
(Martinsried, Germany) and stored at -20°C in 10 mM Tris-HCl pH 8.0. Dilutions 
were made in DEPC-treated water (Ambion). The TAR construct consisted of 29-mer 
RNA oligonucleotide with sequence: 
5’-GGCAGAUCUGAGCCUGGGAGCUCUCUGCC-3’. 
The cTAR construct consisted of its DNA complementary sequence: 
5’-GGCAGAGAGCTCCCAGGCTCAGATCTGCC-3’. 
When specified, TAR and cTAR were labeled at the 5’ and 3’ ends respectively 
by the fluorophore 5-carboxyfluorescein (FAM) and the dark quencher 4-(4’-
dimethylaminophenylazo)benzoic acid (Dabcyl).  
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Full-length recombinant NC protein was obtained as previously reported [45].  
Protein concentration was determined by using a Lambda 20 (Perkin Elmer) UV-vis 
spectrophotometer using an extinction coefficient at 280 nm of 6410 M
-1
 cm
-1
.  
(9H-fluoren-9-yl)methyl 2-chloro-2-oxoethylcarbamate (2a; Fmoc-Gly-Cl). 
Commercially available Fmoc-Gly-OH (Aldrich®, 2.5g, 8.40 mmol) was 
dissolved in anhydrous dichloromethane (40 mL) in a two-neck flask. Excess SOCl2 
(5 mL; 68.54mmol) was added dropwise. The mixture was heated at reflux for 30 
minutes. Solvent was evaporated under reduced pressure and the residue was purified 
by crystallization from n-hexane, which afforded 2.57 g of pure 2a as a white solid. 
Yield: 97%.                                                             
(S)-(9H-fluoren-9-yl)methyl 1-chloro-1-oxopropan-2-ylcarbamate (2b; Fmoc-L-
Ala-Cl).  
This compound was obtained by adopting the same procedure used for 2a, 
starting from Fmoc-L-Ala-OH and SOCl2. Yield: 98%. White solid. 
(R)-(9H-fluoren-9-yl)methyl 1-chloro-1-oxopropan-2-ylcarbamate (2c; Fmoc-D-
Ala-Cl).  
This compound was obtained by adopting the same procedure used for 2a, 
starting from Fmoc-D-Ala-OH and SOCl2. Yield: 99%. White solid. 
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N,N'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(2-aminoacetamide)-bis-
trifluoroacetate (3a). 
Fmoc-Gly-Cl (2a, 7 g, 19.4 mmol) and pyridine (1.27 mL, 15.8 mmol) were 
slowly added to a solution of 2,6-diaminoanthraquinone (1, 350 mg, 1.94 mmol) in 
DMF (80 mL). The reaction mixture was stirred at room temperature for 24 hours. 
Solvent was removed by reduced pressure distillation. The residue was purified by 
crystallization from ethyl acetate, thus obtaining 2,6-bis[N-(2-Fmoc-amino)-
acetamide]anthracene-9,10-dione (2,6-Fmoc-Gly-anthraquinone) as an orange 
powder (1.4 g, 1.68 mmol, yield 88%), which was used in the next step without any 
further purification. This compound was reacted with a 33% diethylamine solution in 
THF (60 mL) for 2 hours. Solvent was again distilled off under reduced pressure and 
the residue was finally reacted with a solution of trifluoroacetic acid in water (9:1, 
v/v, 20 mL) for 1 hour. Reaction mixture was then added with diethyl ether (60 mL). 
The precipitate was collected by centrifugation and dried to obtain 920 mg of 
intermediate 3a as an intense orange solid. Yield 78% (overall). 
1
H-NMR, 
13
C-NMR 
and MS were consistent to that already reported in literature [46]. 
(2S,2'S)-N,N'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(2-amino-
propanamide)-bis-trifluoroacetate (3b). 
This compound was obtained by adopting the same procedure used for 3a, 
starting from Fmoc-L-Ala-Cl and 2,6-diamminoanthraquinone. Orange solid. Yield: 
75% (overall). 
1
H-NMR (DMSO-d6): δ 11.26 (bs, 2H), 8.49 (d, 2H), 8.31 - 8.21 (m, 
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8H), 8.08 (dd, 2H), 2.70 (d, 6H), 2.52 (m, 2H). 
13
C NMR (DMSO- d6): δ 181.1, 
165.8, 143.6, 134.3, 128.6, 128.4, 123.6, 115.8, 49.5, 16.8. ESI-MS: 380.15[M + 
H]+; 191,18[M + 2H]++.  
(2R,2'R)-N,N'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(2-amino-
propanamide)-bis-trifluoroacetate (3c). 
This compound was obtained by adopting the same procedure used for 3a, 
starting from Fmoc-D-Ala-Cl and 2,6-diamminoanthraquinone. Orange solid. Yield: 
73% (overall). 
1
H-NMR (DMSO-d6): δ 11.28 (bs, 2H), 8.49 (d, 2H), 8.30 - 8.20 (m, 
8H), 8.06 (dd, 2H), 2.69 (d, 6H), 2.50 (m, 2H). 
13
C NMR (DMSO- d6): δ 181.2, 
165.6, 143.6, 134.2, 128.4, 128.2, 123.4, 115.5, 49.4, 16.6. ESI-MS: 380.15[M + 
H]+; 191,18[M + 2H]++.  
N,N'-(2,2'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)bis-(2-
oxoethane-2,1-diyl))dipiperidine-4-carboxamide-bis-trifluoroacetate (4a). 
Intermediate 3a (250 mg, 0.42 mmol) was dissolved in dry DMF (18.6 mL), and 
DMAP (545.56 mg, 3.24 mmol), 1-Fmoc-piperidine-4-carboxylic acid (Fmoc-Inp-
OH, 1.00 g, 3.20 mmol), and HBTU (1.36 g, 3.6 mmol) were added. The resulting 
solution was stirred at room temperature for 24 hours, then poured into Et2O and 
centrifuged. The solid obtained was washed with Et2O. The final product was dried in 
vacuo and used in the next step without any further purification. In order to remove 
the Fmoc- protecting group, the solid thus obtained was reacted with a 33% 
diethylamine solution in THF (30 mL) for 2 hours, poured into Et2O and centrifuged. 
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The solid obtained was washed with Et2O and water and then dried in vacuo. 
Subsequently, the obtained solid was reacted with a solution of trifluoroacetic acid in 
water (9:1, v/v, 20 mL) for 1 hour and then poured into Et2O. The resulting 
suspension was centrifuged. The solid obtained was washed with Et2O and dried in 
vacuo. Purification by preparative RP-HPLC afforded the pure compound 4a as an 
intense orange solid. Yield: 79%. Orange solid. K’ (HPLC): 9.10. 1H-NMR (DMSO-
d6, 400MHz): δ 10.71 (s, 2H), 8.67 (t, 2H), 8.46 (d, 2H), 8.36 (bs, 4H), 8.16 (d, 2H), 
8.02 (dd, 2H), 3.76 (d, 4H), 3.27 (m, 4H), 2.91 (m, 4H), 2.54 (m, 2H), 1.90 (m, 4H), 
1.75 (m, 4H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.78, 174.15, 169.25, 158.64, 
144.90, 134.85, 129.05, 128.54, 123.87, 116.24, 43.23, 42.89, 38.98, 25.58. ESI-MS: 
575.2 [M + H]+; 288.3 [M + 2H]++.  
(1R,1'R,4R,4'R)-N,N'-(2,2'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis-
(azanediyl)bis(2oxoethane2,1diyl))bis(4(aminomethyl)cyclohexanecarboxamide)-
bis-trifluoroacetate (4b). 
The compound was obtained by using the same coupling procedure adopted for 
4a, starting from intermediate 3a and trans-4-(Fmoc-aminomethyl)-
cyclohexanecarboxylic acid (N-Fmoc-tranexamic acid). Yield: 57%. Orange solid. K’ 
(HPLC): 9.4 
1
H-NMR (DMSO-d6, 400MHz): δ 10.68 (s, 2H), 8.46 (d, 2H), 8.13 (d, 
2H), 8.01 (dd, 2H), 7.91 (t,  2H), 7.76 (bs, 6H), 3.98 (d, 4H), 3.33 m (2H), 2.54 (s, 
4H), 1.69 (m, 2H), 1.14 (m, 8H), 0.88 (m, 8H). 
13
C-NMR (DMSO-d6, 400MHz): δ 
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182.09, 173.90, 171.23, 145.29, 135.05, 129.21, 128.42, 124.13, 116.31, 45.72, 
43.36, 37.82, 35.63 29.55, 29.06. ESI-MS: 630.8 [M + H]+; 315.9  [M + 2H]++. 
N,N'-(2,2'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)bis(2-oxo-
ethane-2,1-diyl))bis(4-aminopiperidine-4-carboxamide)-tetratrifluoroacetate 
(4c). 
The compound was obtained by using the same coupling procedure adopted for 
4a, starting from the intermediate 3a and 1-Fmoc-4-(Fmoc-amino)-piperidine-4-
carboxylic acid (Fmoc-Pip(Fmoc)-OH). Yield: 70%. Orange solid. K’ (HPLC): 5.8. 
1
H-NMR (DMSO-d6, 400MHz): δ 10.68 (s, 2H), 8.94 (bs, 4H), 8.65 (bs, 6H), 8.53 (t, 
2H), 8.45 (d, 2H), 8.13 (d, 2H), 8.03 (dd, 2H), 3.98 (d, 4H), 3.24 (m, 4H), 2.85 (m, 
4H), 2.40 (m, 4H), 1.96 (m, 4H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.98, 171.07, 
168.92, 145.32, 135.04, 129.20, 128.68, 124.19, 116.42, 56.88, 43.25, 35.71, 28.96. 
ESI-MS: 604.9[M + H]+; 303.1 [M + 2H]++. 
N,N'-(2,2'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)bis(2-oxo-
ethane-2,1-diyl))bis(3-aminopropanamide)-bis-trifluoroacetate (4d). 
The compound was obtained by using the same coupling procedure adopted for 
4a, starting from the intermediate 3a and Fmoc-β-Alanine-OH (Fmoc-β-Ala-OH). 
Yield: 79%. Yellow solid. K’ (HPLC): 3.5. 1H-NMR (DMSO-d6, 400MHz): δ 
10.68(s, 2H), 8.54 (t, 2H), 8.45 (d, 2H), 8.16 (d, 2H), 8.04 (dd, 2H), 7.45 (bs, 6H), 
3.98 (d, 4H), 2.97 (t, 4H), 2.52 (t, 4H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.78, 
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170.76, 169.17, 144.83, 134.86, 129.06, 128.61, 123.96, 116.35, 43.33, 36.03, 33.01. 
ESI-MS: 494.9 [M + H]+; 248.2 [M + 2H]++. 
N,N'-(2,2'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)bis(2-oxo-
ethane-2,1-diyl))bis(2,3-diaminopropanamide)-tetra-trifluoroacetate (4e). 
The compound was obtained by using the same coupling procedure adopted for 
4a, starting from intermediate 3a and N
α
-Fmoc-N
β
-Boc-L-2,3-diaminopropionic acid 
(Fmoc-Dap(Boc)-OH). Yield: 83%. Yellow solid. K’ (HPLC): 3.40. 1H-NMR 
(DMSO-d6, 400MHz): δ 10.88 (s, 2H), 8.97 (bs, 8H), 8.46 (t, 2H), 8.19 (d, 2H), 8.17 
(d, 2H), 8.04 (dd, 2H), 4.12 (d, 4H), 3.16 (m, 4H), 2.47 (m, 2H). 
13
C-NMR (DMSO-
d6, 400MHz): δ 181.75, 168.69, 158.76, 144.63, 134.86, 129.09, 128.75, 124.08, 
116.43, 62.23, 44.18, 41.61. ESI-MS: 525.2 [M + H]+; 263.2 [M + 2H]++. 
N,N'-(2,2'-(9,10-dioxo-9,10-dihydroanthracene-2,7-diyl)bis(azanediyl)bis(2-oxo-
ethane-2,1-diyl))bis(2,4-diaminobutanamide)-tetra-trifluoroacetate (4f). 
The compound was obtained by using the same coupling procedure adopted for 
4a, starting from intermediate 3a and N
α
-Fmoc-N
γ
-Boc-L-2,4-diaminobutyric acid 
(Fmoc-Dab(Boc)-OH). Yield: 86%. Yellow solid. K’ (HPLC): 3.26. 1H-NMR 
(DMSO-d6, 400MHz): δ 10.90 (s, 2H), 9.03 (t, 2H), 8.48 (bs, 6H), 8.21 (d, 2H), 8.19 
(bs, 6H), 8.17 (d, 2H), 7.99 (dd, 2H), 3.99 (d, 4H), 2.98 (m, 2H), 2.05 (m, 4H), 1.24 
(m, 4H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.80, 168.78, 168.56, 144.72, 134.88, 
129.10, 128.70, 123.90, 116.28, 50.32, 43.18, 35.43, 29.47. ESI-MS: 553.1 [M + 
H]+; 277.2 [M + 2H]++. 
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N,N'-(2,2'-(9,10-dioxo-9,10-dihydroanthracene-2,7-diyl)bis(azanediyl)bis(2-oxo-
ethane-2,1-diyl))bis(2,5-diaminopentanamide)-tetra-trifluoroacetate (4g). 
  The compound was obtained by using the same coupling procedure adopted for 
4a, starting from intermediate 3a and N
α
-Fmoc-N
δ
-Boc-L-ornithine (Fmoc-Orn(Boc)-
OH). Yield: 80%. Yellow solid. K’ (HPLC): 3.94. 1H-NMR (DMSO-d6, 400MHz): δ 
10.78 (s, 2H), 8.66 (t, 2H), 8.52 (d, 2H), 8.25 (bs, 6H), 8.16 (d, 2H), 8.04 (dd, 2H), 
7.96 (bs, 6H), 3.98 (d, 4H), 3.42 (m, 4H), 2.68 (m, 2H), 1.65 (m, 4H), 1.53 (m, 4H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.88, 169.38, 168.57, 144.55, 134.72, 129.04, 
128.66, 124.22, 116.45, 52.12, 43.20, 38.85, 28.47, 22.78. ESI-MS: 581.1 [M + H]+; 
291.3 [M + 2H]++. 
 
N,N'-(2,2'-(9,10-dioxo-9,10-dihydroanthracene-2,7-diyl)bis(azanediyl)bis(2-oxo-
ethane-2,1-diyl))bis(2,6-diaminohexanamide)-tetra-trifluoroacetate(4h). 
  The compound was obtained by using the same coupling procedure adopted for 
4a, starting from intermediate 3a and N
α
-Fmoc-N
ε-
Boc-L-Lysine(Fmoc-Lys(Boc)-
OH. Yield: 84%. Yellow solid. K’ (HPLC): 3.81. 1H-NMR (DMSO-d6, 400MHz): δ 
10.85 (s, 2H), 8.92 (t, 2H), 8.21 (bs, 6H), 8.18 (d, 2H), 8.16 (d, 2H), 8.03 (dd, 2H), 
7.82 (bs, 6H), 4.04 (d, 4H), 3.87 (m, 2H), 2.76 (m, 4H), 1.75 (m, 4H), 1.56 (m, 4H), 
1.41 (m, 4H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.88, 171.12, 169.08, 145.23, 
135.23, 129.12, 128.78, 124.04, 116.53, 52.20, 38.63, 35.38, 28.78, 23.02. ESI-MS: 
609.01 [M + H]+; 305.3 [M + 2H]++. 
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N,N'-(2,2'-(9,10-dioxo-9,10-dihydroanthracene-2,7-diyl)bis(azanediyl)bis(2-oxo-
ethane-2,1-diyl))bis(2-amino-3-(4-aminophenyl)propanamide)-tetra-
trifluoroacetate(4i). 
The compound was obtained by using the same coupling procedure adopted for 
4a, starting from intermediate 3a and Boc-4-(Fmoc-amino)-L-phenylalanine (Boc-4-
(NH-Fmoc)-Phe-OH). Yield: 77%. Orange solid. K’ (HPLC): 3.85. 1H-NMR 
(DMSO-d6, 400MHz): δ 10.82 (s, 2H), 8.96 (t, 2H), 8.47 (bs, 6H), 8.19 (d, 2H), 8,17 
(d, 2H), 8.15 (bs, 6H), 8.04 (dd, 2H), 7.17 (d, 4H), 6.91 (d, 4H), 4.07 (d, 4H), 3.07 
(m, 2H), 2.91 (m, 4H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.79, 169.20, 168.57, 
158.72, 144.76, 134.88, 130.92, 129.13, 128.68, 128.61, 123.99, 118.97, 116.36, 
53.94, 43.36, 36.87. ESI-MS: 677.2 [M + H]+; 339.2 [M + 2H]++. 
N,N'-(((9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl))bis(2-oxo-
ethane-2,1-diyl))bis(2-amino-3-(4-hydroxyphenyl)propanamide), 2,2,2-trifluoro-
acetate salt  (4l). 
The compound was obtained by using the same coupling procedure adopted for 4a, 
starting from the intermediate 3a and N-(9-Fluorenylmethoxycarbonyl)-O-tert-butyl-
L-tyrosine (Fmoc-Tyr(tBU)-OH. Yield: 69%. Orange solid. K
’
(HPLC): 3.96.  
1
H-
NMR (DMSO-d6, 400MHz): δ 
1
H-NMR (DMSO-d6, 400MHz): δ 10.85 (s, 2H), 8.22 
(t, 2H), 8.18 (d, 2H), 8.17 (d, 2H), 8.02 (dd, 2H), 7.19 (d, 4H), 6.82 (d,4H), 6.74 (bs, 
6H), 5.15 (bs, 2H), 4.04 (d, 4H), 3.87 (m, 2H), 2.76 (m, 4H). 
13
C-NMR (DMSO-d6, 
400MHz): δ 181.88, 171.12, 169.08, 155.7, 145.23, 135.23, 129.12, 128.78, 128.68, 
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128.61, 124.04, 118.83, 116.53, 52.20, 38.63, 35.38. ESI-MS: 679.2 [M + H]+; 340.2 
[M + 2H]++. 
 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)-
bis(1-oxopropane-2,1-diyl)dipiperidine-4-carboxamide-bis-trifluoroacetate (5a). 
Intermediate 3b (250 mg, 0.42 mmol) was dissolved in dry DMF (18.6 mL), 
and DMAP (545.56 mg, 3.24 mmol), 1-Fmoc-piperidine-4-carboxylic acid (Fmoc-
Inp-OH, 1.00 g, 3.20 mmol), and HBTU (1.36 g, 3.6 mmol) were added. The 
resulting solution was stirred at room temperature for 24 hours, then poured into Et2O 
and centrifuged. The solid obtained was washed with Et2O and the final product was 
dried in vacuo and used in the next step without any further purification. In order to 
remove the Fmoc- protecting group, the solid obtained was reacted with a 33% 
diethylamine solution in THF (30 mL) for 2 hours, poured into Et2O and centrifuged. 
The solid obtained was washed with Et2O and water and then dried in vacuo. 
Subsequently, the obtained solid was reacted with a solution of trifluoroacetic acid in 
water (9:1, v/v, 20 mL) for 1 hour and then poured into Et2O. The resulting 
suspension was centrifuged. The solid obtained was washed with Et2O and dried in 
vacuo. Purification by preparative RP-HPLC afforded the pure compound 5a as an 
intense orange solid. Yield: 79%. Orange solid. K’ (HPLC): 6.3. 1H-NMR (DMSO-
d6, 400MHz): δ 10.70 (s, 2H), 8.71 (t, 2H), 8.45 (bs, 4H), 8.34 (d, 2H), 8.14 (bs, 4H), 
8.04 (dd, 2H), 4.37 (m, 2H), 3.26 (m, 4H), 2.85 (m, 4H), 1.82 (m, 4H), 1.69 (m, 4H), 
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1.31 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz):  δ 181.78, 172.06, 168.72, 144.89, 
134.82, 129.05, 128.69, 124.11, 116.45, 51.90, 50,01, 40.58, 38.72, 28.69, 23.01, 
18.31. ESI-MS: 603.3 [M + H]+; 302.1 [M + 2H]++. 
(1R,1'R,4S,4'S)-N,N'-((2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6-
diyl)-bis(azanediyl)bis(1oxopropane2,1diyl))bis-(4(aminomethyl)cyclohexane-
carboxamide)-bis-trifluoroacetate (5b). 
The compound was obtained by using the same coupling procedure adopted for 
5a, starting from intermediate 3b and 4-(Fmoc-aminomethyl)cyclohexanecarboxylic 
acid (N-Fmoc-tranexamic acid). Yield: 67%. Orange solid. K’ (HPLC): 6.2. 1H-NMR 
(DMSO-d6, 400MHz): δ 10.67 (s, 2H), 8.46 (t, 2H), 8,16 (d, 2H), 8.14 (d, 2H), 8.06 
(dd, 2H), 7.76 (bs, 6H), 4.38 (m, 2H), 2.84 (m, 4H), 2.64 (m, 2H), 1.77 (m, 2H), 1.68 
(m, 8H), 1.31 (d, 6H), 0.89 (m, 8H). 
13
C-NMR (DMSO-d6, 400MHz): δ 182.04, 
172.44, 171.85, 144.69, 135.01, 129.17, 128.52, 124.13, 116.41, 51.84, 43.96, 38.02, 
35.69 29.65, 29.13, 17.96. ESI-MS: 659.1 [M + H]+; 330.2 [M + 2H]++. 
N,N'-(1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)bis(1-oxo-
propane-2,1-diyl))bis(4-aminopiperidine-4-carboxamide)-tetra-trifluoroacetate 
(5c). 
The compound was obtained by using the same coupling procedure adopted for 
5a, starting from intermediate 3b and 1-Fmoc-4-(Fmoc-amino)-piperidine-4-
carboxylic acid (Fmoc-Pip(Fmoc)-OH). Yield: 66%. Orange solid. K’ (HPLC): 4.7. 
1
H-NMR (DMSO-d6, 400MHz): δ 10.69 (s, 2H), 8.45 (t, 2H), 8.32 (d, 2H), 8.18 (bs, 
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4H), 8.15 (d, 2H), 8.02 (dd, 2H), 7.92 (bs, 6H), 4.32 (m, 2H), 3.57 (m, 4H), 3.14 (m, 
4H), 2.86 (m, 4H), 2.70 (m, 4H), 1.31 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 
182.05, 171.33, 169.12, 145.23, 134.99, 129.24, 128.62, 124.23, 116.46, 56.88, 
51.23, 35.71, 28.96, 17.93. ESI-MS: 633.4 [M + H]+; 317.2 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6diyl)bis(azanediyl)bis-
(1-oxopropane-2,1-diyl)bis(2,4-diaminobutanamide)-tetra-trifluoroacetate (5d). 
The compound was obtained by using the same coupling procedure adopted for 
5a, starting from the intermediate 3b and Fmoc-β-Alanine-OH (Fmoc-β-Ala-OH). 
Yield: 82%. Yellow solid. K’ (HPLC): 3.9. 1H-NMR (DMSO-d6, 400MHz): δ 10.86 
(s, 2H), 8.94 (t, 2H), 8.48 (d, 2H), 8.19 (d, 2H), 8.06 (dd,, 2H), 7.78 (bs, 6H), 4.56 
(m, 2H), 2.81 (m, 4H), 1.75 (m, 4H), 1.39 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 
181.98, 171.16, 169.44, 144.98, 134.86, 129.26, 128.61, 124.06, 116.53, 51.33, 
36.03, 33.01, 18.13. ESI-MS: 523.5 [M + H]+; 262.1 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6diyl)bis(azanediyl)-
bis(1-oxopropane-2,1-diyl)bis(2,3-diaminopropanamide)-tetra-trifluoroacetate 
(5e). 
The compound was obtained by using the same coupling procedure adopted for 
5a, starting from intermediate 3b and N
α
-Fmoc-Nβ-Boc-L-diaminopropionic acid 
(Fmoc-Dap(Boc)-OH). Yield: 86%. Orange solid. K’ (HPLC): 4.8. 1H-NMR 
(DMSO-d6, 400MHz): δ 10.92 (s, 2H), 9.01 (t, 2H), 8.47 (bs, 6H), 8.20 (bs, 6H), 8.17 
(d, 2H), 8.06 (d, 2H), 8.04 (dd, 2H), 4.54 (m, 2H), 4.20 (m, 2H), 3.15 (m, 4H), 1.42 
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(d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.81, 172.19, 158.77, 145.65, 134.81, 
129.07, 128.85, 124.26, 116.61, 50.82, 50.36, 40.15, 18.30. ESI-MS: 553.5 [M + 
H]+; 277.2 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)-
bis(1-oxopropane-2,1-diyl)bis(2,4-diaminobutanamide)-tetra-trifluoroacetate 
(5f). 
The compound was obtained by using the same coupling procedure adopted for 
5a, starting from intermediate 3b and N
α
-Fmoc-N
γ
-Boc-L-diaminobutyric acid 
(Fmoc-Dab(Boc)-OH). Yield: 78%. Orange solid. K’ (HPLC): 4.6. 1H-NMR 
(DMSO-d6, 400MHz): δ 10.84 (s, 2H), 8.86 (t, 2H), 8.45 (bs, 6H), 8.17 (d, 2H), 8.16 
(d, 2H), 8.05 (dd, 2H), 7.78 (bs, 6H), 4.51 (m, 2H), 3.84 (m, 2H), 2.82 (m, 4H), 1.75 
(m, 4H), 1.40 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.87, 171.98, 168.66, 
145.32, 134.88, 129.09, 128.77, 124.24, 116.55, 50.85, 50.32, 35.43, 29.47, 18.13. 
ESI-MS: 581.4 [M + H]+; 291.3 [M + 2H]++. 
N,N'-(1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)bis(1-oxo-
propane-2,1-diyl))bis(2,5-diaminopentanamide)-tetra-trifluoroacetate (5g). 
The compound was obtained by using the same coupling procedure adopted for 
5a, starting from intermediate 3b and N
α
-Fmoc-N
δ
-Boc-L-ornithine (Fmoc-Orn(Boc)-
OH). Yield: 82%. Orange solid. K’ (HPLC): 4.7. 1H-NMR (DMSO-d6, 400MHz): δ 
10.87 (s, 2H), 8.87 (t, 2H), 8.46 (bs, 6H), 8.18 (d, 2H), 8.16 (d, 2H), 8.07 (dd, 2H), 
7.86 (bs, 6H), 4.50 (m, 2H), 3.86 (m, 2H), 3.16 (m, 4H), 2.82 (m, 4H), 1.77 (m, 4H), 
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1.40 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 182.02, 169.78, 168.17, 144.75, 
134.23, 129.09, 128.68, 124.24, 116.47, 52.12, 50.24, 38.85, 28.47, 22.78, 18.19. 
ESI-MS: 609.4 [M + H]+; 305.4 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydro-anthracene-2,6diyl)bis(azanediyl)-
bis(1-oxopropane-2,1-diyl)bis-(2,6-diaminohexanamide)-tetra-trifluoroacetate 
(5h). 
The compound was obtained by using the same coupling procedure adopted for 5a, 
starting from intermediate 3b and N
α
-Fmoc-N
ε
-Boc-L-Lysine (Fmoc-Lys(Boc)-OH. 
Yield: 84%. Orange solid. K’ (HPLC): 4.7. 1H-NMR (DMSO-d6, 400MHz): δ 10.85 
(s, 2H), 8.86 (t, 2H), 8.45 (bs, 6H), 8.18 (d, 2H), 8.16 (d,  2H), 8.06 (dd, 2H), 7.79 
(bs, 6H), 4.49 (q, 2H), 3.86 (m, 2H), 2.74 (m, 4H), 1.73 (m, 4H), 1.54 (m, 4H), 1.39 
(d, 6H), 1.34 (m, 4H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.88, 172.20, 168.92, 
158.72, 144.92, 134.83, 129.08, 128.67, 124.06, 116.43, 52.22, 50.03, 38.96, 30.88, 
26.91, 21.49, 18.10. ESI-MS: 636.9 [M + H]+; 319.1 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6diyl)bis(azanediyl)bis-
(1-oxopropane-2,1-diyl)bis(2-amino-3-(4-aminophenyl)propanamide)-tetra-
trifluoroacetate (5i). 
The compound was obtained by using the same coupling procedure adopted for 
5a, starting from intermediate 3b and Fmoc-4-(Boc-amino)-L-phenylalanine (Fmoc-
4-(NH-Boc)-OH). Yield: 72%. Orange solid. K’ (HPLC): 4.8. 1H-NMR (DMSO-d6, 
400MHz): δ 10.78 (s, 2H), 8.75 (t, 2H), 8.47 (bs, 6H), 8.18 (d, 2H), 8.15 (d, 2H), 8.04 
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(dd, 2H), 7.01 (d, 4H), 6.97 (d, 4H), 6.74 (bs, 6H), 4.45 (m, 2H), 4.00 (m, 2H), 2.91 
(m, 4H), 1.23 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 182.09, 169.72, 168.37, 
158.33, 144.46, 134.98, 130.96, 129.03, 128.88, 128.61, 123.99, 118.87, 116.52, 
53.94, 50.33, 36.87, 18.03. ESI-MS: 705.4 [M + H]+; 353.3 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2diyl)bis(azanediyl)bis(1-
oxopropane-2,1-diyl)bis(azanediyl)bis(3-(4-hydroxyphenyl)-1-oxopropan-2-
aminium) 2,2,2-trifluoroacetate (5l). 
The compound was obtained by using the same coupling procedure adopted for 
5a, starting from intermediate 3b and N-(9-Fluorenylmethoxycarbonyl)-O-tert-butyl-
L-tyrosine (Fmoc-Tyr(tBU)-OH. Yield: 57%. Orange solid. K’ (HPLC): 5.79. 1H-
NMR (DMSO-d6, 400MHz): δ 
1
H-NMR (DMSO-d6, 400MHz): δ 10.85 (s, 2H), 8.22 
(t, 2H), 8.18 (d, 2H), 8.17 (d, 2H), 8.02 (dd, 2H), 7.19 (d, 4H), 6.82 (d,4H), 6.74 (bs, 
6H), 5.14 (bs, 2H), 4.23 (m, 2H), 3.84 (m, 2H), 2.76 (m, 4H), 1.23 (d, 6H). 
13
C-NMR 
(DMSO-d6, 400MHz): δ 181.86, 170.89, 168.98, 155.6, 145.25, 135.33, 129.11, 
128.78, 128.68, 128.60, 124.02, 118.78, 116.49, 51.20, 37.63, 35.40, 18.4. ESI-MS: 
707.9 [M + H]+; 354.8 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)-
bis(1-oxopropane-2,1-diyl)dipiperidine-4-carboxamide-bis-trifluoroacetate (6a). 
Intermediate 3c (250 mg, 0.42 mmol) was dissolved in dry DMF (18.6 mL), 
and DMAP (545.56 mg, 3.24 mmol), 1-Fmoc-piperidine-4-carboxylic acid (Fmoc-
Inp-OH, 1.00 g, 3.20 mmol), and HBTU (1.36 g, 3.6 mmol) were added. The 
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resulting solution was stirred at room temperature for 24 hours, then poured into Et2O 
and centrifuged. The solid obtained was washed with Et2O and the final product was 
dried in vacuo and used in the next step without any further purification. In order to 
remove the Fmoc- protecting group, the solid obtained was reacted with a 33% 
diethylamine solution in THF (30 mL) for 2 hours, poured into Et2O and centrifuged. 
The solid obtained was washed with Et2O and water and then dried in vacuo. 
Subsequently, the obtained solid was reacted with a solution of trifluoroacetic acid in 
water (9:1, v/v, 20 mL) for 1 hour and then poured into Et2O. The resulting 
suspension was centrifuged. The solid obtained was washed with Et2O and dried in 
vacuo. Purification by preparative RP-HPLC afforded the pure compound 6a as an 
intense orange solid. Yield: 76%. Orange solid. K’ (HPLC): 5,5. 1H-NMR (DMSO-
d6, 400MHz): δ 10.71 (s, 2H), 8.71 (t, 2H), 8.44 (bs, 4H), 8.33 (d, 2H), 8.14 (bs, 4H), 
8.03 (dd, 2H), 4.37 (m, 2H), 3.24 (m, 4H), 2.84 (m, 4H), 1.83 (m, 4H), 1.68 (m, 4H), 
1.31 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz):  δ 181.79, 172.07, 168.73, 144.89, 
134.82, 129.04, 128.68, 124.11, 116.44, 51.90, 50,02, 40.59, 38.72, 28.68, 23.02, 
18.31. ESI-MS: 603.3 [M + H]+; 302.1 [M + 2H]++. 
(1R,1'R,4S,4'S)-N,N'-((2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6-
diyl)-bis(azanediyl)bis(1oxopropane2,1diyl))bis-(4(aminomethyl)cyclohexane-
carboxamide)-bis-trifluoroacetate (6b). 
The compound was obtained by using the same coupling procedure adopted for 
6a, starting from intermediate 3c and 4-(Fmoc-aminomethyl)cyclohexanecarboxylic 
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acid (N-Fmoc-tranexamic acid). Yield: 65%. Orange solid. K’ (HPLC): 6.4. 1H-NMR 
(DMSO-d6, 400MHz): δ 10.69 (s, 2H), 8.47 (t, 2H), 8,18 (d, 2H), 8.16 (d, 2H), 8.05 
(dd, 2H), 7.77 (bs, 6H), 4.36 (m, 2H), 2.85 (m, 4H), 2.64 (m, 2H), 1.76 (m, 2H), 1.67 
(m, 8H), 1.31 (d, 6H), 0.88 (m, 8H). 
13
C-NMR (DMSO-d6, 400MHz): δ 182.02, 
172.43, 171.83, 144.69, 135.03, 129.18, 128.52, 124.11, 116.41, 51.82, 43.97, 38.02, 
35.67 29.66, 29.13, 17.95. ESI-MS: 659.1 [M + H]+; 330.2 [M + 2H]++. 
N,N'-(1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)bis(1-oxo-
propane-2,1-diyl))bis(4-aminopiperidine-4-carboxamide)-tetra-trifluoroacetate 
(6c). 
The compound was obtained by using the same coupling procedure adopted for 
6a, starting from intermediate 3c and 1-Fmoc-4-(Fmoc-amino)-piperidine-4-
carboxylic acid (Fmoc-Pip(Fmoc)-OH). Yield: 63%. Orange solid. K’ (HPLC): 4.7. 
1
H-NMR (DMSO-d6, 400MHz): δ 10.69 (s, 2H), 8.46 (t, 2H), 8.31 (d, 2H), 8.18 (bs, 
4H), 8.15 (d, 2H), 8.03 (dd, 2H), 7.90 (bs, 6H), 4.34 (m, 2H), 3.58 (m, 4H), 3.14 (m, 
4H), 2.85 (m, 4H), 2.71 (m, 4H), 1.31 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 
182.04, 171.37, 169.08, 145.22, 135.00, 129.21, 128.59, 124.19, 116.45, 56.87, 
51.23, 35.72, 28.96, 17.94. ESI-MS: 633.4 [M + H]+; 317.2 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6diyl)bis(azanediyl)bis-
(1-oxopropane-2,1-diyl)bis(2,4-diaminobutanamide)-tetra-trifluoroacetate (6d). 
The compound was obtained by using the same coupling procedure adopted for 
6a, starting from the intermediate 6c and Fmoc-β-Alanine-OH (Fmoc-β-Ala-OH). 
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Yield: 81%. Yellow solid. K’ (HPLC): 4.1. 1H-NMR (DMSO-d6, 400MHz): δ 10.85 
(s, 2H), 8.91 (t, 2H), 8.48 (d, 2H), 8.18 (d, 2H), 8.07 (dd,, 2H), 7.78 (bs, 6H), 4.54 
(m, 2H), 2.82 (m, 4H), 1.75 (m, 4H), 1.38 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 
181.99, 171.16, 169.46, 144.96, 134.87, 129.25, 128.61, 124.07, 116.55, 51.33, 
36.02, 33.03, 18.13. ESI-MS: 523.5 [M + H]+; 262.1 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6diyl)bis(azanediyl)-
bis(1-oxopropane-2,1-diyl)bis(2,3-diaminopropanamide)-tetra-trifluoroacetate 
(6e). 
The compound was obtained by using the same coupling procedure adopted for 
6a, starting from intermediate 3c and N
α
-Fmoc-N
β
-Boc-L-diaminopropionic acid 
(Fmoc-Dap(Boc)-OH). Yield: 86%. Orange solid. K’ (HPLC): 4.8. 1H-NMR 
(DMSO-d6, 400MHz): δ 10.92 (s, 2H), 9.00 (t, 2H), 8.47 (bs, 6H), 8.19 (bs, 6H), 8.18 
(d, 2H), 8.06 (d, 2H), 8.04 (dd, 2H), 4.55 (m, 2H), 4.21 (m, 2H), 3.15 (m, 4H), 1.43 
(d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.81, 172.169, 158.77, 144.65, 134.81, 
129.07, 128.85, 124.26, 116.61, 50.82, 50.36, 40.15, 18.30. ESI-MS: 553.5 [M + 
H]+; 277.2 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)-
bis(1-oxopropane-2,1-diyl)bis(2,4-diaminobutanamide)-tetra-trifluoroacetate 
(6f). 
The compound was obtained by using the same coupling procedure adopted for 
6a, starting from intermediate 3c and N
α
-Fmoc-N
γ
-Boc-L-diaminobutyric acid 
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(Fmoc-Dab(Boc)-OH). Yield: 79%. Orange solid. K’ (HPLC): 4.8. 1H-NMR 
(DMSO-d6, 400MHz): δ 10.81 (s, 2H), 8.87 (t, 2H), 8.45 (bs, 6H), 8.17 (d, 2H), 8.16 
(d, 2H), 8.04 (dd, 2H), 7.78 (bs, 6H), 4.53 (m, 2H), 3.82 (m, 2H), 2.84 (m, 4H), 1.75 
(m, 4H), 1.41 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.88, 172.01, 168.69, 
145.33, 134.87, 129.11, 128.73, 124.24, 116.55, 50.86, 50.31, 35.41, 29.48, 18.13. 
ESI-MS: 581.4 [M + H]+; 291.3 [M + 2H]++. 
N,N'-(1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6-diyl)bis(azanediyl)bis(1-oxo-
propane-2,1-diyl))bis(2,5-diaminopentanamide)-tetra-trifluoroacetate (6g). 
The compound was obtained by using the same coupling procedure adopted for 
6a, starting from intermediate 3c and N
α
-Fmoc-N
δ
-Boc-L-ornithine (Fmoc-Orn(Boc)-
OH). Yield: 81%. Orange solid. K’ (HPLC): 4.8. 1H-NMR (DMSO-d6, 400MHz): δ 
10.88 (s, 2H), 8.86 (t, 2H), 8.46 (bs, 6H), 8.18 (d, 2H), 8.16 (d, 2H), 8.06 (dd, 2H), 
7.85 (bs, 6H), 4.51 (m, 2H), 3.85 (m, 2H), 3.16 (m, 4H), 2.83 (m, 4H), 1.77 (m, 4H), 
1.41 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.99, 169.76, 168.13, 144.74, 
134.24, 129.09, 128.69, 124.24, 116.49, 52.13, 50.24, 38.84, 28.44, 22.79, 18.18. 
ESI-MS: 609.4 [M + H]+; 305.4 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydro-anthracene-2,6diyl)bis(azanediyl)-
bis(1-oxopropane-2,1-diyl)bis-(2,6-diaminohexanamide)-tetra-trifluoroacetate 
(6h). 
The compound was obtained by using the same coupling procedure adopted for 5a, 
starting from intermediate 3c and N
α
-Fmoc-N
ε
-Boc-L-Lysine (Fmoc-Lys(Boc)-OH. 
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Yield: 83%. Orange solid. K’ (HPLC): 4.9. 1H-NMR (DMSO-d6, 400MHz): δ 10.86 
(s, 2H), 8.86 (t, 2H), 8.44 (bs, 6H), 8.18 (d, 2H), 8.16 (d,  2H), 8.06 (dd, 2H), 7.78 
(bs, 6H), 4.50 (q, 2H), 3.85 (m, 2H), 2.75 (m, 4H), 1.72 (m, 4H), 1.54 (m, 4H), 1.40 
(d, 6H), 1.33 (m, 4H). 
13
C-NMR (DMSO-d6, 400MHz): δ 181.87, 172.19, 168.90, 
158.75, 144.93, 134.84, 129.09, 128.67, 124.08, 116.44, 52.22, 50.04, 38.97, 30.88, 
26.93, 21.48, 18.12. ESI-MS: 636.9 [M + H]+; 319.1 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2,6diyl)bis(azanediyl)bis-
(1-oxopropane-2,1-diyl)bis(2-amino-3-(4-aminophenyl)propanamide)-tetra-
trifluoroacetate (6i). 
The compound was obtained by using the same coupling procedure adopted for 
6a, starting from intermediate 3c and Fmoc-4-(Boc-amino)-L-phenylalanine (Fmoc-
4-(NH-Boc)-OH). Yield: 69%. Orange solid. K’ (HPLC): 5.1. 1H-NMR (DMSO-d6, 
400MHz): δ 10.74 (s, 2H), 8.74 (t, 2H), 8.44 (bs, 6H), 8.18 (d, 2H), 8.15 (d, 2H), 8.02 
(dd, 2H), 7.01 (d, 4H), 6.94 (d, 4H), 6.72 (bs, 6H), 4.44 (m, 2H), 4.00 (m, 2H), 2.88 
(m, 4H), 1.22 (d, 6H). 
13
C-NMR (DMSO-d6, 400MHz): δ 182.05, 169.72, 168.36, 
158.32, 144.45, 134.95, 130.94, 129.03, 128.84, 128.58, 123.93, 118.84, 116.52, 
53.93, 50.31, 36.87, 18.03. ESI-MS: 705.2 [M + H]+; 353.1 [M + 2H]++. 
N,N'-(2S,2'S)-1,1'-(9,10-dioxo-9,10-dihydroanthracene-2diyl)bis(azanediyl)bis(1-
oxopropane-2,1-diyl)bis(azanediyl)bis(3-(4-hydroxyphenyl)-1-oxopropan-2-
aminium) 2,2,2-trifluoroacetate (6l). 
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The compound was obtained by using the same coupling procedure adopted for 
6a, starting from intermediate 3c and N-(9-Fluorenylmethoxycarbonyl)-O-tert-butyl-
L-tyrosine(Fmoc-Tyr(tBU)-OH. Yield: 62%. Orange solid. K’ (HPLC): 5.8. 1H-NMR 
(DMSO-d6, 400MHz): δ 
1
H-NMR (DMSO-d6, 400MHz): δ 10.86 (s, 2H), 8.24 (t, 
2H), 8.18 (d, 2H), 8.17 (d, 2H), 8.02 (dd, 2H), 7.18 (d, 4H), 6.84 (d,4H), 6.73 (bs, 
6H), 5.14 (bs, 2H), 4.22 (m, 2H), 3.85 (m, 2H), 2.74 (m, 4H), 1.24 (d, 6H). 
13
C-NMR 
(DMSO-d6, 400MHz): δ 181.87, 170.87, 168.96, 155.53, 145.24, 135.33, 129.09, 
128.77, 128.69, 128.62, 124.04, 118.78, 116.47, 51.21, 37.63, 35.42, 18.3. ESI-MS: 
707.9 [M + H]+; 354.8 [M + 2H]++. 
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4.2 High Throughput Screening (HTS) 
The ability of each compound to stabilize nucleic acids was measured by the 
increase of melting temperature of the oligonucleotide in presence of each 
anthraquinone. Melting temperature (Tm) is the temperature at which 50% molecules 
of oligonucleotide are denatured. TAR, cTAR or annealed TAR/cTAR formed by 
thermal denaturation [47] were folded at 10 µM in TNMg (Tris-HCl 10 mM, NaCl 20 
mM, Mg(ClO4)2 1 mM pH 7.5) and then diluted to 1 µM concentration in ETN 
(EDTA 1 mM, Tris HCl 10 mM, NaCl 20 mM, pH 7.5). In each microplate well, the 
nucleic acid solutions were mixed with the anthraquinones solutions to the final 
concentrations of 1, 10 and 100 μM. Nucleic acid solutions without compound were 
used to measure the reference Tm value. The melting protocol consisted of a melting 
phase, in which the temperature increased from 25 °C to 99 °C in 1 h (0.02 °C/s). 
Fluorescence emission of FAM was read by using a Light Cycler 480 II (Roche) 
with emission at λ=510 nm and correlated to the melting temperature of the 
oligonucleotide. The Tm value was mathematically derived from the thermal 
denaturing profile by using LC480 software. ΔTm was calculated by using the 
following equation: ∆Tm = Tm2 - Tm1, where Tm2 and Tm1 are the Tm values 
measured by testing the oligonucleotides (or the hybrid) in the presence or absence of 
compound, respectively. 
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4.3 Fluorescence Quenching Assay (FQA) 
High Throughput Screening (HTS) was performed to identify inhibitors of NC 
chaperone activity on either TAR or cTAR. We used a Victor III (Perkin Elmer) 
microplate reader with 485 and 535 nm as excitation and emission wavelengths. A 1 
µM aliquot of either TAR or cTAR, which bore 5’-FAM and 3’-DAB modifications, 
was heat refolded in TNMg (Tris-HCl 10 mM, NaCl 20 mM, Mg(ClO4)2 1 mM pH 
7.5). Briefly, the oligonucleotides were denatured at 95 °C for 5 min and then left to 
cool to room temperature in order to assume their stem-bulge-loop structure. The 
samples were then diluted to 0.1 µM in TN (Tris-HCl 10 mM, NaCl 20 mM pH 7.5). 
Increasing concentrations of compound (0, 0.1, 0.5, 1, 5, 10, 50, 100 µM final) were 
added to each sample before introducing NC to a final concentration of 0.8 µM (for a 
1:8 oligo to NC molar ratio). The plate was read three times with 1 min intervals, 
unless differently specified. The experimental data were fitted as reported earlier to 
enable calculation of the respective IC50 value. Each experiment was performed in 
triplicate to calculate an average and standard deviation. 
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4.4 Nucleocapsid Annealing Mediated Electrophoresis (NAME) assay 
Nucleocapsid Annealing Mediated Electrophoresis (NAME) assay was developed 
to investigate the ability of compounds to impair the biological activity of the full-
length NC protein, which involved monitoring the annealing of TAR with cTAR. 
Solutions containing 1µM concentrations of TAR, cTAR and the hybrid TAR/cTAR 
were heat re-folded in TNMg (Tris-HCl 10 mM, NaCl 20 mM, Mg(ClO4)2 1 mM pH 
7.5). Briefly, the oligonucleotides were denatured at 95 °C for 5 min and then left to 
cool to room temperature in order to assume their stem-bulge-loop (TAR and cTAR) 
or double-stranded (hybrid TAR/cTAR) structure. Two different assay formats were 
employed to evaluate the inhibition of NC-mediated TAR/cTAR hybrid formation: 
NC-preincubation. Full-length recombinant NC protein (8 μM) was preincubated 
with increasing concentrations (0, 1, 10, 20, 50, 100 μM final concentrations) of each 
anthraquinone derivative for 15 min at room temperature. Folded TAR (1 μM) and 
cTAR (1 μM) were mixed with the NC-anthraquinone solutions and then incubated 
for 15 min at room temperature. The samples were added with Gel Loading Buffer 
containing SDS (GLBSDS: Tris-HCl 100 mM, EDTA 4 mM, 50% w/v glycerol, 2% 
w/v SDS, 0.05% w/v bromophenol blue), kept on ice and finally resolved on a 12% 
native PAGE (Acrylamide:Bisacrylamide = 19:1) in TBE buffer (Tris 89 mM, Boric 
acid 89 mM and EDTA 2 mM, pH 8) for 3 h at 200 V. 
Oligo-preincubation. TAR (1 μM) and cTAR (1 μM) were folded separately as 
described above and then individually preincubated with increasing concentrations of 
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compound (each oligo with 0, 1, 10, 20, 50, 100 μM final concentrations) for 15 min 
at room temperature. Aliquots of each construct were mixed together, added with NC 
solution (8 μM), and then incubated for other 15 min at room temperature. The 
samples were added with Gel Loading Buffer containing SDS (GLBSDS: Tris-HCl 
100 mM, EDTA 4 mM, 50% w/v glycerol, 2% w/v SDS, 0.05% w/v bromophenol 
blue), kept on ice, and finally analyzed on a 12% native PAGE (19:1 acrylamide to 
bisacrylamide ratio) in TBE buffer (Tris 89 mM, Boric acid 89 mM and EDTA 2 
mM, pH 8) for 3 h at 200 V. 
After electrophoresis, all gels were stained with SybrGreen II and analyzed on a 
Geliance 600 Imaging System (PerkinElmer). Gene Tools software (PerkinElmer) 
was employed to quantify the percentage of hybrid formation, which enabled the 
calculation of the sought-after IC50 value, namely the concentration of compound 
required to inhibit hybrid formation by half. 
 
4.5 ESI-MS analysis 
TAR and cTAR were separately folded in 150 mM ammonium acetate (pH 7.5) 
containing 1μM MgCl2. The oligonucleotides were denatured at 95 °C for 5 min and 
then left to cool to room temperature in order to assume their stem-bulge-loop 
structure. Before mixing with compounds, folded TAR and cTAR were filtered by 
using 3K NMWL (Millipore Corporation, MA, USA) centrifugal filters to minimize 
the presence of magnesium salts that can adversely interfere with ESI performance. 
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Samples for binding studies were prepared by mixing appropriate volumes of folded 
TAR or cTAR (1 µM final) with each compound in 150 mM ammonium acetate (pH 
7.5). The final mixtures contained up to a 10:1 of 2,6 dipeptidyl-anthraquinone: 
substrate molar ratio. In order to establish the binding equilibrium in solution, 
samples were incubated for 15 min at room temperature before the analysis. Control 
experiments were performed on 1 µM solutions of TAR or cTAR in 150 mM 
ammonium acetate, and 10 µM solutions of each compound in 150 mM ammonium 
acetate.  
The 4a, 4g, 4h and 5a, 5g, 5h compounds were selected as representatives of the 
2,6-AQ-Gly-X and of the 2,6-AQ-L-Ala-X series, respectively. All samples were 
analyzed in negative ion mode by direct infusion electrospray ionization (ESI) on a 
Thermo Fisher Scientific (West Palm Beach, CA) LTQ-Orbitrap Velos mass 
spectrometer. The analyses were performed in nanoflow ESI mode by using quartz 
emitters produced in-house by a Sutter Instruments Co. (Novato, CA) P2000 laser 
pipette puller. Up to 6 µL samples were loaded onto each emitter by using a gel 
loader pipette tip. A stainless steel wire was inserted in the back-end of the emitter 
and used to supply an ionizing voltage ranged around 0.8-1.0 kV. Source temperature 
and desolvation conditions were adjusted to decrease the incidence of salt adducts, 
with typical source temperature of 200 °C. Data were processed by using Xcalibur 
2.1 software (Thermo Scientific). 
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The new series of compounds were tested at the Department of Pharmaceutical 
Sciences of the Padua University, by the research group of  Prof. Barbara Gatto, in 
order to verify their ability to inhibit the formation of the Tat-TAR complex and the 
chaperonic activity of NC protein, included its role of mediator in the annealing 
reaction of TAR with cTAR. 
Compounds were evaluated by different assays: 
 High Throughput Screening (HTS); 
 Fluorescence Quenching Assay (FQA); 
 NAME Assay (Nucleocapsid Annealing-Mediated Electrophoreis). 
Moreover, in order to extend the spectrum of information related to the 
interaction between the synthesized compounds and nucleic acids of interest, 
compounds were evaluated in ESI-MS studies performed at the RNA Institute- 
University of New York, under the supervision of  Prof. Dan Fabris. 
For compounds belonging to 2,6-AQ-D-Ala-X series, as well as for the 
derivatives characterized by the presence of a tyrosine residue (compounds 4l, 5l and 
6l), we didn’t receive to date biological results and therefore this PhD thesis reports 
the results related to the compounds of  2,6-AQ-Gly-X (compounds 4a-4i)  and 2.6-
AQ-L-Ala-X(5a-5i). 
 
 
82 
 
5.1  2,6-Dipeptidyl-anthraquinones intercalate into TAR and cTAR 
dynamic structures (High Throughput Screening) 
The research group to which I belong recently reported that the TAR and 
cTAR stabilization effect of the previously synthetized 2,6-AQ-βAla-X series of 
anthraquinonic derivatives leads to the inhibition of NC [43].  
On this background, novel compounds were evaluated by High Throughput 
Screening studies, that  have been performed to achieve preliminary identification of 
compounds able to stabilize the strands of TAR and cTAR.  
Assuming a direct correlation between melting temperature and nucleic acid-
binding activity, this setup allowed us to investigate the ability of compounds 4a-4i 
and 5a-5i to modify the thermal denaturing profile of initial TAR and cTAR. 
Reference Tm values were determined in the absence of ligand, which amounted to 
69.3 °C for TAR, 53.8 °C for cTAR, and 69.4 °C for the hybrid. The melting profile 
of TAR, cTAR, and annealed heteroduplex were obtained to evaluate the shift of 
melting temperature (ΔTm) in the presence of increasing concentrations of 
anthraquinones. Sample solutions contained 1 μM of each nucleic acid substrate and 
1, 10 or 100 μM of each ligand. Figure 12 and 13 summarize the values of ΔTm 
obtained respectively from the 2,6-AQ-Gly-X and 2,6-AQ-L-Ala-X series in the 
presence of a 10 μM ligand concentration, which displayed the most significant 
deviations.  
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Figure 12: Variations of melting temperature (ΔTm) manifested by TAR, cTAR and TAR/cTAR hybrid in 
the presence of peptidyl-anthraquinones 4a-4i. Reported values are the mean ± standard error of the mean 
(SEM) of triplicate experiments performed on samples containing 1 μM of oligonucleotide and 10 μM of 
ligand. 
 
Figure 13: Variations of melting temperature (ΔTm) manifested by TAR, cTAR and TAR/cTAR hybrid in 
the presence of peptidyl-anthraquinones 5a-5i. Reported values are the mean ± standard error of the mean 
(SEM) of triplicate experiments performed on samples containing 1 μM of oligonucleotide and 10 μM of 
ligand. 
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The results clearly revealed that derivatives of either series stabilized to different 
extent the structures of tested nucleic acids. In the case of the 2,6-AQ-Gly-X series, 
the length of the alkyl chain with two protonable amino groups correlated with the 
increased melting temperature according to the 4e < 4f < 4g < 4h ranking.  The 
increases displayed by the TAR and cTAR constructs were particularly significant in 
the presence of 4g and 4h, whereas weaker stabilization was achieved by 4a, 4c, 4d, 
4e and 4f. In contrast, 4b and 4i produced no detectable effect on Tm, thus suggesting 
that their putative binding may not induce structure stabilization. Overall, this series 
induced slightly lower Tm shifts on TAR than cTAR, while those induced on the 
TAR/cTAR duplex were significantly lower, thus suggesting that the hybrid-
stabilizing effects were less prominent.  
The greater stabilization of TAR and cTAR is consistent with the hypothesis that 
disubstituted anthraquinones selectively recognize dynamic structures of nucleic 
acids, such as the bulge-loop features of these constructs, as expected from threading 
intercalators [49-51]. 
Compounds 5a-5i (2,6-AQ-L-Ala-X) were analyzed in the same manner to 
investigate whether the introduction of a methyl group in side chains would affect 
nucleic acids recognition and stabilization.  
In this case, 5f, 5g and 5h were identified as strong TAR and cTAR stabilizers, 
while the other analogues did not produce significant effects. The 5e compound 
displayed no detectable activity. In analogy with glycine supporting derivatives, the 
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L-alanine compounds showed greater stabilization as the length of the side chains 
increased, with the following rank: 5e < 5f < 5g. However, this trend was not present 
when proceeding from the ornithine (i.e., 5g) to the lysine anchor (i.e., 5h), since the 
latter introduced lower stabilization than the former.  
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5.2 2,6-Dipeptidyl-anthraquinones inhibit NC-melting of TAR and 
cTAR structure (Florescence Quenching Assay) 
Because the two series of derivatives stabilize the structures of nucleic acids, 
which represent the substrates of NC protein during the transcription, we analyzed 
their anti-NC properties in vitro through an assay based on fluorescence, consisting of 
a modification of the FRET protocol. 
In particular, Florescence Quenching Assay is a FRET-based competition assay 
performed using the Tat-derived peptide labeled with the donor “fluorescein” at its 
N-terminus and the 29 nt TAR labeled at its 3’ end with the dark quencher “dabcyl”. 
This assay is based on the possibility that protein NC, inducing the fusion of the 
lower half of the TAR strand, increases the distance between the fluorophore and 
quencher, leading to an increase in fluorescence. So, every inhibition of  
destabilization  activities of NC protein, related to interaction with the ligand, can be 
directly assessed by fluorescence quenching. 
After preliminary studies, designed to verify the absence of direct quenching of 
anthraquinonic compounds, it was possible to assess their inhibitory activity in the 
presence of  the full length of recombinant NC protein of HIV-1 virus.  
Tables 3 and 4 report the concentrations that produced half maximal inhibition of 
TAR and cTAR destabilization mediated by NC, which were observed for 4a−4i and 
5a−5i, respectively. 
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Table 1: IC50 values observed for the 4a-4i inhibition of NC-mediated melting of TAR and cTAR. 
Compound IC50 TAR 
(µM) 
IC50 cTAR 
(µM) 
4a 10.71±1.6 10.67±0.12 
4b 11.33±0.34 9.75±1.72 
4c 7.79±0.80 5.13±1.21 
4d 6.42±0.05 4.06±1.49 
4e 4.22±0.35 3.81±1.34 
4f 3.87±0.18 4.61±0.17 
4g 2.62±0.32 1.81±0.23 
4h 2.12±0.16 1.11±0.19 
4i 7.72±1.12 7.78±0.86 
             
 
 
Table 2: IC50 values observed for the 5a-5i inhibition of NC-mediated melting of TAR and cTAR.   
 
 
Compound 
IC50 TAR 
(µM) 
IC50 cTAR 
(µM) 
5a 20.80±6.75 11.97±4.27 
5b 14.80±3.83 14.64±2.20 
5c 40.25±1.98 14.59±0.42 
5d 39.50±2.08 12.71±1.68 
5e 67.12±1.61 44,15±1.43 
5f 6.90±0.51 4.28±0.27 
5g 4.91±0.48 1.93±0.50 
5h 6.61±0.51 2.68±0.47 
5i 7.29±1.14 7.53±0.85 
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The results obtained from the 2,6-AQ-Gly-X series evidenced that, with the sole 
exception of 4a and 4b, all derivatives with glycine spacers were potent inhibitors of 
the NC-mediated melting, which exhibited IC50 values lower than 10 µM. In 
particular, 4g and 4h were the most active inhibitors of NC, with IC50s of 2.62 µM 
and 2.12 µM with TAR, and 1.81 µM and 1.11 µM with cTAR.  
These results corroborated the strong stabilization of these constructs revealed 
by the HTS experiments. Consistent with the HTS results, the length of the doubly 
charged side chains correlated well with the potency of inhibition with both TAR and 
cTAR, according to the 4h > 4g > 4f > 4e rank.  
Although members of the 2,6-AQ-L-Ala-X series were also found capable of 
inhibiting NC-mediated melting, they displayed weaker activity than the 
corresponding 2,6-AQ-Gly-X counterparts. In this case, the ornithine (5g) and lysine 
(5h) derivatives were among the most active inhibitors in the series, either when TAR 
or cTAR were assayed, but their activities were lower than those of the corresponding 
4g and 4h analogues.  
These results were unexpected. Since 5a-5i compounds showed a greater ability 
in binding and stabilizing TAR and cTAR construct compared to their glycine-spacer 
analogues, we expected a greater NC inhibition. This expectation was not verified 
and this apparent discrepancy could be rationalized on the basis of the location of the 
putative binding sites for the threading intercalators onto the nucleic acid constructs. 
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Our experimental results suggest that ligand binding did not necessarily compete 
with NC interactions with the nucleic acid constructs. Hence, the introduction of a 
methyl group, which changed side chains maintaining the same length, leads to lower 
NC-mediating TAR and cTAR melting inhibition. 
    
5.3   2,6-Dipeptidyl-anthraquinones inhibit NC-mediated TAR/cTAR annealing 
(Nucleocapsid Annealing-Mediated Elettrophoresis) 
NC possesses more complex activities in addition to the destabilization of 
nucleic acid structures: NC promotes the annealing of nucleic acid strands. While the 
destabilization phase was appropriately analyzed by using the FRET-based platform, 
the strand re-annealing process was evaluated by using our recently developed 
Nucleocapsid Annealing-Mediated Electrophoresis (NAME) assay [52].  
This type of experiment can be used to identify molecules capable of inhibiting 
the NC-mediated melting and annealing of viral nucleic acids folded into stable 3D 
conformations [53].   
Oligonucleotides without the need of their previous labeling are used to perform 
this electrophoretic assay, avoiding unspecific compounds-fluorophore interactions. 
The NAME protocol allows the analysis of the TAR/cTAR annealing reaction in 
the presence of NC and was used here to evaluate the impairment of the TAR/cTAR 
hybrid formation by compounds that strongly stabilize TAR and cTAR constructs. 
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The NAME assay was performed in two different modes. The first relied on 
preincubation of compounds with the full-length NC for 15 min, followed by the 
addition of the folded oligonucleotides for other 15 min (NC-preincubation mode). 
The second involved preincubating the compounds for 15 min with each folded 
nucleic acid substrate, followed by addition of NC and further 15 min incubation 
(Oligo-preincubation mode).  
In this way, the overall incubation time remained constant in either mode, but 
alternative preincubation with protein or folded constructs gave us the opportunity to 
detect possible differences in the mechanisms of action of related compounds [54]. 
Compounds 4a-4i and 5a-5i were analyzed in both modes. Representative data 
obtained by performing NAME assays in the presence of 4h and 5g are reported in 
Figures 14 and 15, respectively.  
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Figure 14: Inhibition of the TAR/cTAR annealing reaction by 4h derivative of the 2,6-AQ-Gly-X series. 
NAME assay was completed in Oligo-preincubation mode on the left and in NC-preincubation mode on the 
right as above described. TAR, cTAR and the hybrid TAR/cTAR formed by thermal denaturation were used 
as control. Increasing concentrations (0, 1, 5, 10, 20, 50, 100 µM final) of 4h were used to inhibit the activity 
of the full-length recombinant NC protein. 
 
 
Figure 15: Inhibition of the TAR/cTAR annealing reaction by 5g derivative of the 2,6-AQ-L-Ala-X series. 
NAME assay was completed in Oligo-preincubation mode on the left and in NC-preincubation mode on the 
right as above described. TAR, cTAR and the hybrid TAR/cTAR formed by thermal denaturation were used 
as control. Increasing concentrations (0, 1, 5, 10, 20, 50, 100 µM final) of 5g were used to inhibit the activity 
of the full-length recombinant NC protein. 
 
92 
 
This first analysis by NAME allowed us to obtain indications on the putative 
mechanism of action of the identified NC inhibitors. Comparing the results obtained 
in the two different NAME assay modes, it is evident that the Oligo-preincubation 
favored the inhibitory activity of anthraquinones, thus suggesting that their 
mechanism of action relied on the direct interaction with the nucleic acids substrates, 
rather than with NC. A thorough examination of these data allowed us to group 
together compounds that exhibited similar activity. In particular, 4g and 4h (Figure 
16)  resulted to be highly active in the 20-50 µM concentration range, while 4c, 4d, 
4e, 4f, 5g and 5h exhibited moderate NC inhibition in the 50-100 µM range (Figure 
17); all the other derivatives resulted to be inactive up to 100 µM concentration (data 
not shown).  
 
Figure 16: Inhibition of the TAR/cTAR annealing reaction by compounds exhibiting activity in the 20-50 
µM concentration range. NAME assay performed in the Oligo-preincubation mode in the presence of 4g (A) 
and 4h (B). TAR, cTAR and the hybrid TAR/cTAR formed by thermal denaturation were used as control. 
Increasing concentrations (0, 1, 5, 10, 20, 50, 100 µM final) of anthraquinone were used to inhibit the 
activity of the full-length recombinant NC protein. 
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Figure 17: Inhibition of the TAR/cTAR annealing reaction by compounds exhibiting activity in the 50-100 
µM concentration range. NAME assay performed in the Oligo-preincubation mode in the presence of 4c (A), 
4d (B), 4e (C), 4f (D), 5g (E) and 5h (F). TAR, cTAR and the hybrid TAR/cTAR formed by thermal 
denaturation were used as control. Increasing concentrations (0, 1, 5, 10, 20, 50, 100 µM final) of 
anthraquinone were used to inhibit the activity of the full-length recombinant NC protein. 
 
We therefore focused on active compounds and the more active ones were 
further investigated in the Oligo-preincubation mode to evaluate the influence of 
concentration.  
In order to determine accurately the IC50 values afforded by the various 
anthraquinones, two different sets of concentrations were selected for highly active 
compounds (0, 1, 10, 20, 30, 40, 50, 75, 100 µM final) or moderately active 
compounds (0, 1, 10, 25, 50, 60, 70, 80, 100 µM final).  
94 
 
Among the inactive compounds identified by the preliminary screening, 4i and 
5f were employed in these experiments as negative controls.  
Results from three independent analyses were assessed to calculate the IC50, as a 
measure of the ability of these compounds to slow down the annealing activity of NC 
under the selected experimental conditions (Table 3). 
         Table 3:  IC50 values observed for the inhibition of NC-mediated annealing of TAR and cTAR (NAME assay).  
 
Compound 
IC50 NAME 
(µM) 
Compound 
IC50 NAME 
(µM) 
4a ND 5a ND 
4b ND 5b ND 
4c >100 5c ND 
4d >100 5d ND 
4e 102.7±7.5 5e ND 
4f 81.4±2.3 5f >100 
4g 54.1±12.5 5g 49.1±15.9 
4h 23.5±9.8 5h 80.4±8.6 
4i >100 5i ND 
 
          
The results provided by these NC-mediated annealing experiments proved that 
tested dipeptidyl-anthraquinones are annealing inhibitors. Interestingly, these results 
matched those achieved from the NC-mediated melting assays and the relative 
potencies of annealing inhibition follow exactly the same order obtained in the 
melting inhibition. 
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Indeed, as the length of the doubly-charged side chains increased in the 2,6-AQ-
Gly-X series, the efficacy of inhibition increased according to the 4h < 4g < 4f < 4e 
rank.  In contrast, this trend was verified in the 2,6-AQ-L-Ala-X series only for 5e < 
5f < 5g, whereas the NC-inhibition potency decreases again when proceeding from 
5g to 5h. In addition, the NAME assays confirmed that 2,6-AQ-Gly-X 
anthraquinones were in general more potent than the 2,6-AQ-L-Ala-X derivatives, 
suggesting the importance of the spacer length related to the activities of these 
compounds, highlighted 4h and 5g as the strongest inhibitors within either series. 
 
5.4  2,6-Dipeptidyl-anthraquinones bind to TAR and cTAR (ESI-MS) 
Additional insights into the specific interactions of 2,6-dipeptidyl-
anthraquinones with nucleic acids were obtained by evaluating the binding properties 
of selected compounds identified by the FQA determinations. With the goal of 
assessing the stoichiometry and overall affinity of such compounds for TAR and 
cTAR, we analyzed ligand-substrate mixtures by electrospray ionization mass 
spectrometry (ESI-MS) under conditions that enable the detection of intact non-
covalent complexes of oligonucleotides [55-59].  
All the samples were analyzed in negative ionization mode by direct infusion. 
Preliminary control determinations were performed on TAR and cTAR samples 
in negative ion mode, which afforded experimental masses of 9286.2 and 8884.5 u, 
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respectively. These values matched very closely the monoisotopic values calculated 
from the respective sequences (i.e., 9286.3 Da and 8884.5 Da).  
Increasing amounts of ligand were added to a 1 μM solution of either construct, 
in such a way as to obtain samples containing up to a 10:1 molar ratio of ligand 
versus substrate.  
Based on the strong stabilizing activity revealed by the FQA experiments, the 
4g, 4h and 5g, 5h compounds were selected as representatives of the 2,6-AQ-Gly-X 
and 2,6-AQ-L-Ala-X series, respectively. In addition, 4a and 5a were also included 
as possible negative controls, owing to their weak stabilization effects. 
The representative data reported in Figure 18 show only the regions containing 
the 7- and 6- charge states of TAR and cTAR in the presence of 4h and 5g. The 
spectra displayed signals corresponding to free unbound constructs, as well as those 
of stable complexes with different stoichiometries. 
 
 
 
 
97 
 
 
Figure 18: Representative ESI-MS spectra of samples obtained by mixing 1 μM of either TAR or cTAR 
with 10 μM of 2,6 dipeptidyl-anthraquinone in 150 mM ammonium acetate. Panel A) was obtained from a 
sample containing 4h and TAR; B) 4h and cTAR; C) 5g and TAR; and D) 5g and cTAR. The 
stoichiometries of the observed complexes are indicated in each spectrum. Signals of lower intensity detected 
near free/bound species consist of typical sodium and ammonium adducts. 
 
These results confirmed the ability of ESI-MS to preserve the non-covalent 
interactions established by peptidyl-anthraquinonic derivatives with dynamic nucleic 
acid structures.  
Experimental and calculated masses for all the species detected in these 
experiments are provided in Table 4 and 5. 
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Table 4: Monoisotopic mass (Da) of 2,6 dipeptidyl-anthraquinone: TAR complexes by ESI-MS analysis. 
 
 
Table 5: Monoisotopic mass (Da) of 2,6 dipeptidyl-anthraquinone: cTAR complexes by ESI-MS analysis. 
 
 
The experimental mass is obtained considering the monoisotopic peak of each 
complex; the theoretical calculated mass is obtained from the oligonucleotide 
sequence and the elemental composition of the ligand. The experimental masses are 
calculated from the negative ion mode spectra obtained for 10:1 2,6 dipeptidyl-
anthraquinone: TAR or 2,6 dipeptidyl-anthraquinone: cTAR  molar ratio in 150 mM 
ammonium acetate. 
The determination of free and bound RNA or DNA, necessary to evaluate the 
binding affinity of compounds to TAR and cTAR, was directly assessed from the 
intensity of the respective peaks divided by the charge state. Taking into 
consideration all the charge states observed for each species offsets the effects of a 
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shift of charge state distribution, which manifests itself as compensatory changes in 
the relative signal intensities of successive charge states. Normalizing the signal 
intensity by the respective charge state constitutes a simple  way to reduce the 
possible bias due to the fact that different charge states induce different image 
currents during ion detection in ESI-MS. Free and complexed TAR or cTAR 
abundances were finally expressed as percentage and compared. 
The results obtained by ESI-MS clearly revealed that the selected 2,6-
dipeptidyl-anthraquinones could bind either substrate with different stoichiometries, 
thus suggesting the presence of multiple binding sites on the selected constructs. In 
particular, the coexistence of free TAR or cTAR with complexes of different 
stoichiometries indicated that binding to the second site was initiated before 
saturation of the first was complete, which is consistent with independent sites 
sharing similar affinities and negligible cooperativity. Similar binding modes were 
detected for all the TAR and cTAR complexes observed for the analyzed compounds. 
The partitioning between free and bound species in each sample served not only 
to understand the putative binding modes supported by the constructs, but also to 
estimate their overall affinity towards the different ligands.  
The percentage of complexed over total substrate in each sample was calculated 
to obtain relative scales of binding affinities for TAR and cTAR, respectively: 4g ≈ 
5g ≈ 5h > 4h >> 4a ≈ 5a and 5g ≈ 5h > 4h > 4g >> 4a ≈ 5a. In addition, the fact that 
the percentage of complexed substrate was consistently lower in the TAR than in the 
cTAR experiments at the same ligand concentrations indicated that all compounds 
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possessed greater affinities for the DNA than for the RNA construct, in accordance 
with HTS results (Figure 12 and 13). 
These experiments showed also that stronger ligands produced greater binding 
stoichiometries. The strongest TAR binders 4g, 5g and 5h displayed up to 3:1 ratios, 
whereas only 1:1 complexes were detected for 4a and 5a at the same ligand 
concentrations (Figure 19). 
 
Figure 19:  ESI-MS spectra of samples obtained by mixing either TAR or cTAR with 2,6 
dipeptidyl-anthraquinones.  Panel A) was obtained from a sample containing 4a and TAR; B) 4a 
and cTAR; C) 4g and TAR; D) 4g and cTAR; E) 5a and TAR; F) 5a and cTAR; G) 5h and TAR; 
H) 5h and cTAR. The stoichiometry of bound species is reported in each spectrum. Lower intensity 
signals near free/bound species consist of typical sodium and ammonium adducts. 
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In the case of cTAR construct, the strongest binders 5g and 5h displayed up to 
4:1 complexes, whereas complexes up to only 2:1 were detected for the weaker 4a 
and 5a binders (Figure 19).  Analyzing in details the data it is evident how binding 
stoichiometries and affinities observed by ESI-MS experiments possessed excellent 
correlation with the stabilization of TAR and cTAR folding detected by Fluorescence 
Quencing Assay (FQA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
102 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
Conclusion 
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The results obtained during my PhD at the Deparment of Pharmacy of the 
University of Naples Federico II have led to the identification of new promising 
classes of NC inhibitors. Having the goal of finding NC inhibitors, we identified 
novel 2,6-diaminoanthraquinonic derivatives able to bind and stabilize preferentially 
dynamic regions of nucleic acids like TAR and cTAR over annealed duplexes [60].  
Based on precise structural requirements placing charged substituents at the 2,6-
positions of the anthraquinones ring, the presence of two charged residues in each 
flexible side chain at the distance of three to four methylene groups, we have 
discovered potent in vitro inhibitors of NC, as demonstrated through all the in vitro 
studies with full length NC. 
The new derivatives differ from previously reported ones by the length and 
identity of the linker between the anthraquinone ring and the charged groups on the 
side chains. The compounds were obtained by following an excellent synthetic 
scheme that provided high yields and purity. 
Comparing the structures of the two series with different linkers, we can 
conclude that the presence of an Orn residue in the side chain grants very favorable 
features to enhance the inhibitory activity of both anthraquinone series tested.  
This conclusion is supported by the fact that 4g and 5g exhibited high activity in 
both HTS and NAME assays. Consistent with this, the 2,6-AQ-β-Ala-Orn compound 
was also the most active inhibitor in the series described previously [43]. 
 
It is 
important to note, however, that the rank of potencies in the new series 2,6-AQ-Gly-
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X was 4h > 4g > 4f > 4e, which makes 4h, with a Lys as terminal, the lead compound 
in this series. This analogue was highly active in all assays at concentrations 
comparable to those observed for the 2,6-AQ-β-Ala-Orn derivative [43].  
The fact that the longer Lysine, bearing an extra methylene group compared to 
ornitine in the side chain, is better suited than Orn to confer inhibitory properties 
when placed in the 2,6-AQ-Gly-X series suggested that the overall length of the 
peptidic substituent played a determinant role.  
This possibility was supported by examining the distance between the terminal 
amino groups, which are chargeable, and the anthraquinonic scaffold in compounds 
with either β-Ala or Gly linkers. As shown in Figure 20 this examination showed that 
the lengths of the entire peptidic portions of 2,6-AQ-β-Ala-Orn and 2,6-AQ-Gly-Lys 
(4h) were quite similar.  
 
 
 
 
 
 
105 
 
 
Figure 20: Details of the structures of 2,6-AQ-β-Ala-Orn and 4h (2,6-AQ- Gly-Lys), which 
enable a direct comparison of the lengths of the respective side chains. 
 
This observation suggests that proper positioning and orientation of the terminal 
protonated side chains within the anthraquinone-nucleic acid complex must play a 
fundamental role in the inhibition of NC’s chaperone activity. 
In summary, we demonstrated that: 
- the presence of two charged residues in each flexible side chain, with mutual  
distance of three to four methylene groups, is necessary for the development 
of potent NC inhibitors; 
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- Gly linker increases the activity of the 2,6-disubsituted anthraquinones, 
while the presence of an additional methyl group in the L-Ala linker 
decreases activity;  
- in addition to the length, also the orientation of the positively charged side 
chains is important for NC inhibition.  
 
In this direction, additional experiments are underway to explore the possible 
effects of D-Ala linkers (series 2,6-AQ-D-Ala-X compounds 6a-6l) on the activity of 
these anthraquinones. 
In conclusion, 2,6-dipeptidyl-anthraquinones are a promising class of nucleic 
acid-binding compounds that act as NC inhibitors in vitro. We designed, synthesized 
and tested new series of 2,6-disubstituted-anthraquinones, which are able to bind viral 
nucleic acid substrates of NC. We demonstrated that these novel derivatives interact 
preferentially with non-canonical structures of TAR and cTAR, stabilize their 
dynamics structures (such as bulge and loop), and interfere with NC chaperone 
activity. 
The most notable compound consisted of 4h, which acted as TAR and cTAR 
binder, as well as NC inhibitor with activity in the micromolar range. For this 
reasons, 4h can be considered as a “lead compound, with a IC50 value of 2.12 µm. 
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    Abstract Unit 2 
 IGFBP6 is an innovative interesting target: it’s a protein involved in the 
pathogenesis of cancer (breast, prostate, colon, neck and head of the pancreas, 
ovarian cancer and neuroblastoma). It’s chemical features are still not completely 
disclosed, because its crystallographic structure is not available, but several 
informations are accessible from NMR studies: it is composed by three structural 
domains, and either N-terminal residue or C-terminal residue  are rich in cysteines. 
Recent in vivo studies performed in transgenic mice have highlighted the role of 
IGFBP6 in the CNS: in particular, its pathogenic role in the demyelination process, 
certainly interesting, due to its correlation with important pathologies, such as 
multiple sclerosis.  
IGFBP6 can be O-glycosilated and the glycosilation site in represented by C-
terminal residue.  
During my experience at University of Vienna I synthesized a peptide that is 
part of IGFBP6 ([126-153] fragment), suitably modified with Fmoc-Thr(GalNAc-
Ac3)-OH and then iodoacetylated. Moreover my attention was focused to preliminary 
tests aimed to link a photo-cleavable auxiliary to the peptide in order to obtain a 
glycosilated  analogue of IGFBP6 (insulin-like growth factor-binding protein 6).  
These studies allowed to check if  the insertion of the auxiliary could interfere in 
the glycosylation due to the steric hindrance caused by the proximity of the 
glycosylation site and  the N-terminal residue of the peptide. 
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UNIT 2: Synthesis of a PEGylated ligation auxiliary and its 
application in the preparation of homogeneously glycosylated linker 
domain of IGFBP6 protein 
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Chapter 1   
Introduction  
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 Insulin-like growth factors (IGFs), are key elements related to the 
physiological growth and are also implicated in several diseases including cancer.  
There are two different IGFs: IGF-1 and IGF-2, whose activity is modulated by 
a family of high affinity proteins, called IGF Binding Proteins (IGFBP): in particular, 
IGFBP-6 is notable for its marked higher binding affinity for IGF-2 compared  to 
IGF-1. 
The main role of IGFBP6 protein consists in the carrier’s function: indeed, they 
modulate the activity and half-life of IGFs, but recent studies have shown that this 
protein is also able to inhibit angiogenesis and to induce tumor cell migration  (Figure 
1) [60]. 
IGFBP6 owns peculiar structural features: is composed by three structural 
domains, and either N-terminal or C-terminal domains are rich in cysteines. 
All IGFBPs are subject to a large number of post-translational modifications 
that affect their actions, mediated by a large number of protease [61]. 
IGFBP3 and IGFBP4 can be N-glycosylated, whereas IGFBP5 and IGFBP6 
can be O-glycosylated. The glycosylation does not act directly influencing the actions 
of these proteins, but decreases their interaction with glycosaminoglycans, inhibiting 
their proteolytic process. More recently it has been highlighted that the IGFBP6 can 
also be phosphorylated, although the consequences of these changes are still 
unknown [62]. 
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Figure 1: Insulin-like  growth factor-binding protein-6 and cancer [62]. 
Through in vivo studies performed in transgenic mice, it has been also 
highlighted the role of IGFBP6 in the Central Nervous System (CNS): in particular 
its pathogenic role in the demyelination process, certainly interesting, due to its 
linkage with important pathologies, such as multiple sclerosis [62]. 
Moreover, IGFBP6 is involved in the pathogenesis of cancer: breast cancer, 
prostate, colon, neck and head, pancreas, ovarian and neuroblastoma are the diseases 
in which the role of this protein has been explained cleary [63]. 
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Therefore its inhibition can be an interesting target for cancer therapy, above 
all as regards children or young adolescent patients, where a specific IGF-2 receptor 
inhibition appears to be advantageous to block the high IGF-2 autocrine without 
going to inhibit the physiological growth mediated by the presence of IGF-1 [63]. 
IGFBP6 is a O-glycosilated glycoprotein: its structural features derived only 
from NMR studies, in fact are not available yet crystallographic structure: also for 
this reason  could be interesting to deepen the studies about this target. 
Therefore it could be useful to have available analogues of this domain in 
homogeneous form to be able to study features and the role of glycosylation. 
 
 
 
 
 
 
 
 
 
113 
 
 
 
 
 
 
 
 
                   Chapter 2 
                   Aim of the research  
 
 
 
 
 
 
 
 
 
114 
 
During my second year of PhD, I was awarded the STAR Program fellowship 
from “Compagnia di San Paolo” in collaboration with the University of Naples 
Federico II. In the frame of this program, I had the opportunity to spend six months 
working at Department of Biological Chemistry, in the University of Vienna, headed 
by Prof. Christian Becker. 
One of the main interests of the research group where I carried out my 
internship is protein homogeneous, site-selective glycosylation. In particular, Dr. 
Claudia Bello, a postdoc researcher in Prof Becker’s group, developed an innovative 
method using a PEGylated photoclevable ligation auxiliary for the homogeneous, 
sequential glycosilations of Mucin 1 peptides [64]. 
In particular this work allows  the utilization of a photocleavable auxiliary that 
leads easily to attach the PEG polymer to obtain  efficient enzymatic site specifically 
O-glycosylated mucin 1 (MUC1) polypeptides and also it is easily removed by UV 
radiation at 365nm in few minutes.  
From this encouraging scientific starting point, it was decided to apply this 
method to the synthesis and glycosylation of a peptide that is part of IGFBP6, our 
target of interest. 
To this purpose, during the first period of my internship, I focused my attention 
to the synthesis of this auxiliary in higher yields in order to be able to apply this 
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strategy to a new target, the IGFBP6 protein [64]. This synthetic procedure proved to 
be very difficult either in purification and in the characterization steps.  
I then synthesized successfully the [126-153] fragment of the linker domain of 
IGFBP6 and I carried out preliminary experiments for the attachment of the auxiliary 
to the peptide.  
Because of the limited time available, it wasn’t possible to perform the 
enzymatic glycosylation reaction. The project is currently been carried on in the 
Department of Biological Chemistry at the University of Vienna. 
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3.1 Synthesis of the auxiliary  
The synthesis of the auxiliary (compound 13) is summarized in the following 
schemes (Scheme 1 and Scheme 2): 
 
Scheme 1. Synthesis of intermediate 8. Reagents and conditions: I) Methyl 4-chloro butanoate, K2CO3, 
Bu4NI, CH3CN, reflux, 80%. II) HNO3, CH3COOH, 0°C to rt, 93%. III) MePPh3Br, TMS2NNa, THF, 10°C 
to 0°C, 65%. IV) AD-mixα, tBuOH/CH2Cl2/H2O, 90%. V) SOCl2, NEt3,CH2Cl2, 0°C. VI) NaN3, DMF, 60°C. 
VII) PPh3, H2O, THF, 70°C.  
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Scheme 2. Conversion of intermediate 8 in the auxiliary (final compound 13). Reagents and conditions: 
VIII) Boc2O, DMAP, CH3CN, 0°C, 63%. IX) PPh3, DIAD, CH3COSH, THF, 0°C to rt, 84%. X) MeONa, 1-( 
butylthio)-1,2-hydrazine carboxymorpholide, MeOH, rt, 77%. XI) 1,2-ethylenediamine, Zr(OtBu)4, HOBt, 
CH3CN, rt, 70%. XII) a. Fmoc-Cl, DIEA, CH2Cl2, 0°C to rt; b. TFA, CH2Cl2, 92% (two steps). 
 
The synthesis is composed by twelve reaction steps:  in particular 7 synthetic 
steps are referred to Scheme 1 and lead to the  key intermediate 8. The next five 
synthetic steps (Scheme 2) lead to the desired auxiliary (compound 13). 
All  the synthetic details are reported in a previously published paper by Claudia 
Bello and Christian Becker [64]. 
All intermediates were purified by silica gel chromatography and were fully 
characterized by H
1
-NMR, C
13
-NMR and also by bidimensional experiments such as 
COSY; NOESY; HSCQ; HMBC to obtain a complete structural characterization.  
The final derivative (13) was obtained in high reaction yield and in high purity, 
as it is clear evidenced by NMR spectra (H
1
 and C
13
 NMR) represented in Figure 2. 
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Figure 2: H1 and C13 NMR spectra of auxiliary (final compound 13). 
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3.2 Synthesis of IGFBP-6 [126-153] 
The synthesis target, a 27 residues peptide part of IGFBP6, was synthesized on a 
solid support using the 9-fluorenylmethoxycarbonyl (Fmoc)–based Solid Phase 
Peptide Synthesis (SPPS) strategy. The preloaded Alanyl-TentaGel resin Wang type 
was used for the synthesis of the peptide on a 0.1 mmol scale; the synthesis was 
carried out manually and repeated using the Liberty Blue automated microwave 
peptide synthesizer.  
The resin was swollen with DMF for 2h before starting of the synthesis. After 
each coupling the resin was washed with DMF,  MeOH and DCM dried under 
vacuum.  
After the complete synthesis of the peptide: 
ARPQDVNRRDQQRNPGTSTTPSQPNSA 
I did test cleavage to verify the efficiency of the synthesis: 10 mg of peptidyl-
resin were incubated with a mixture of TFA/TIS/H2O (92.5:5:2.5, v/v) for 2h at room 
temperature. 
The free peptide was precipitated by addition of cold diethyl ether and 
centrifugation. Finally, the supernatant was removed and the peptide washed with 
cold diethyl ether, dissolved in a mixture of H2O/CH3CN 1:1(v/v) and analyzed by 
RP-HPLC and HR-ESI-MS (Figure 3).  
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                                           Figure 3: Mass spectrum of the peptide. 
The base pick was consistent with the desired peptide. 
After last alanine coupling, the glycosylated building block represented by 
Fmoc-Thr(GalNAc-Ac3)-OH was coupled to the peptide: the reaction was performed 
using HATU (1.2 eq) as coupling reagent and DIEA(2.5 eq). The resin was incubated 
with the solution of activated modified amino acid for 2h and then washed with 
DMF. 
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Fmoc-Thr(GalNAc-Ac3)-OH was inserted as N-terminal residue, in order to be 
linked with the PEG to perform the desired glycosylation. After Fmoc-Thr(GalNAc-
Ac3)-OH coupling, the resin was washed with DMF, MeOH and DCM and dried 
under vacuum.  A test cleavage was performed to asses the efficiency of coupling of 
the modified amino acid. HR-ESI-MS allowed the characterization of the 
intermediate (Figure 4). 
 
Figure 4: MS spectrum of peptide IGFBP6 [126-153] coupled with Fmoc-Thr(GalNac-Ac3)-OH 
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 N-terminal residue of the peptide was iodoacetylated in order to provide a 
binding site for the auxiliary: the resin was swollen in DMF for 1h, then the Fmoc 
protecting group was removed treating the resin twice with a solution of piperidine 
(20% v/v) in DMF for 3 min and 7 min, respectively.  
After extensive washing with DMF, the resin was incubated with a solution of 
iodoacetic acid and diisopropylcarbodiimide in DMF for 30 min. After removal of the 
supernatant and washing with DMF, the coupling was repeated for 20 min (double 
coupling was performed to obtain the compound in higher yield). 
The test cleavage of the final peptide showed that the desired product was 
obtained in a high purity and in high yield. Therefore, the synthetic strategy proved to 
be excellent (Figure 5). 
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Figure 5: Mass spectrum of the final peptide. 
 
In the latter part of my internship at the University of Vienna, I focused my 
research activity to preliminary tests aimed to link the auxiliary (13) to the final 
peptide: iodoacetylated peptidyl resin was swollen in CH3CN for 3h. DIEA was 
added, followed by the auxiliary (dissolved in a mixture of CH3CN and DMF).  
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The suspension was stirred at 26°C overnight, then the supernatant was removed 
(the unreacted auxiliary was recovered by recrystallization) and the resin washed with 
DMF, DCM and MeOH. Once again a test cleavage was performed to check the 
efficiency of the SN2 reaction. 
The final compound was obtained only in low percentage probably due to steric 
hindrance caused by the proximity of N-terminal of peptide  and  glycosilation site.  
On this hypothesis we decided to further optimize and investigate the linkage 
procedure of the auxiliary to the peptide. 
Prof. Christian Becker and Dr. Claudia Bello are continuing this research project 
with the aim to prepare homogeneously glycosilated  analogues of the linker domain 
of IGFBP6 and, at the same time, discover if  proximity of the auxiliary to the 
glycosylation site might cause problems during the enzymatic glycosylation reaction. 
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